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Three plant species (Phylica paniculata Willd., Pergularia daemia Forssk. and Monsonia
angustifolia E.Mey. ex A. Rich.) were investigated for their anticancer properties. Extracts
from the plants were tested in vitro for cytotoxicity effects against three highly sensitive
cancer cell lines (namely melanoma UACC62, renal TKIO and breast MCF7). In all three
plants, the organic (methanolldichloromethane, I: I v/v) extracts exhibited a significant
inhibition of the growth of cancer cells which warranted further purification to isolate the
active principle(s). Structural elucidation of the active compounds was based on proton
and carbon-13 nuclear magnetic resonance experiments.
Bioassay-guided fractionation of the methanolldichloromethane extract of P. paniculata
resulted in the isolation of ursolic acid as the active constituent along with another
triterpenoid, a-amyrin that showed a weak cytotoxic effect.
Repeated flash chromatography of the organic extract of P. daemia afforded the isolation
of the active coroglaucigenin, a 19-hydroxycardenolide, and four compounds that were
characterized as P-sitosterol, p-sitosteryl glucoside, a-amyrin and 3-0-acetyl-a-amyrin. All
these compounds are reported to have been previously isolated from related plant species.
Although it has been reported that other cardenolides have cytotoxic effects, this is the first
report on the cytotoxicity against cancer cell lines of coroglaucogenin.
Purification of M angustifolia extracts resulted in the isolation of five lignans (viz. 5-
methoxyjusticidin A, justicidin A, chinensinaphthol, retrochinensinaphthol methyl ether
and suchilactone) that previously have been predominantly found in the Justicidin genus.
These compounds were tested for their cytotoxic activity against the cancer cell lines and
two justicidin compounds, 5-methoxyjusticidin A and justicidin A, showed good activity.
5-Methoxyjusticidin A was selected by the National Cancer Institute, USA, for testing in
their 60 cell line screen, but research on this compound was not continued because of lack
of sufficient potency.
The extracts and compounds isolated from M angustifolia were also evaluated in relevant
in vitro and in vivo biological assays for erectile dysfunction and libido. Male rats that
were dosed with the extract mixture (organic and aqueous) demonstrated a significant
increase in mating frequency with female rats as compared to male rats dosed with the
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vehicle control. An increase in the number of pregnant rats as compared to the vehicle
control was also observed. The organic extract was tested in vitro and inhibited the
phosphodiesterase 5 (PDE 5) enzyme and also effectively relaxed the pre-contracted
smooth muscle. The five lignans isolated from the M. angustifolia extract showed varying
degrees of the inhibition of the PDE 5 enzyme. Four compounds, 5-methoxyjusticidin A,
chinesinaphthol, suchilactone and retrochinesinaphthol methyl ether relaxed rabbit corpus
cavernosum smooth muscle significantly. However, in both the above-mentioned in vitro
assays the extracts and isolated compounds displayed a much lower activity that sildenafil
(Viagra). Structural modifications of these lignans may lead to enhanced activity and
bioavailability.
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As a result of inaccessibility to health care facilities, people from disadvantaged
communities often turn to traditional healers (owners of indigenous knowledge) who
prescribe indigenous natural medicines. I This system of medicines needs to be evaluated
scientifically, given due recognition and developed to possibly improve its efficacy and
safety.2
The chemical constituents of most of the local medicinal plants in use are still unknown.
Therefore, it is of importance to characterize the chemical composition of the medicinal
plants and document the indigenous knowledge acquired from the healers or herbalists.
This study will deal with the phytochemical investigation of selected plants that are
endemic to South Africa.
In the past, scientific investigations of folk medicine have led to the development of
marketable products as pharmaceuticals (single component drugs) or nutraceuticals
(botanical extracts) and in the laboratory of natural product chemists, the search for anti-
HIV, antiviral, antitumor, etc. agents continues. South Africa is one of the richest countries
with natural resources (plants, animals, marine organisms and insects) and this biodiversity
has the potential to be a primary source of new leads for drug discovery. Many of the
indigenous plant species used traditionally in South Africa are endemic and consumers are
trading them for their use to a large market, both nationally and internationally.
At the CSIR, plants are being investigated and evaluated for medicinal properties. In this
programme, plants that are received by the CSIR's Bioprospecting research group from
traditional healers and botanists are evaluated for biological activity, specifically anticancer
activity. The information provided to CSIR is governed under collaborative agreements
that also stipulate secrecy of the knowledge provided. The South African National
Biodiversity Institute (SANBI) in Pretoria assists in the identification of the collected
plants. Bioactive compounds are isolated by bioassay-guided fractionation of the plant
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extracts. Unraveling of the complex chemical compositions of the bioactive plants will be
the focus of this study.
In this investigation, three plants from different families were selected for phytochemical
investigation on the basis of their antitumour activity observed in the CSIR's in-house
anticancer screen on three cell lines, namely melanoma, breast and renal cancer cell lines.
The plants under investigation are Phylica paniculata (Rharnnaceae), Pergularia daemia
(Asc1epiadaceae) and Monsonia angustifolia (Geraniaceae).
For each of the three plants, the aim of this study was to:
• Prepare a herbarium specimen for identification by SANBI
• Confirm the biological activity of the plant extracts
• Develop HPLC fingerprinting and TLC methods for guiding fractionation
• Isolation and biological evaluation of the pure compounds
• Elucidation of the structures of the compounds by using NMR spectroscopy and
MS spectrometry
All plant collections were primarily screened for anticancer activity in the available in-
house anticancer screen. Wherever possible, extracts and compounds were also assayed
against other activities. Based on information received from traditional healers, Monsonia





I. Mulaudzi, F.M., 2003. Nursing Update Magazine, 27, 22-24.
2. Cliliabra, S.C., Uiso, F.C. and Mshiu, E. N., 1984. J Ethnopharmacol., 11, 157-179.
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Chapter 2
LITERATURE OVERVIEW OF PLANTS AS A SOURCE OF
ANTICANCER DRUGS AND COMPOUNDS WITH OTHER
PHARMACOLOGICAL PROPERTIES.
2.1. INTRODUCTION TO CANCER
Cancer is a disease that begins in cells that are behaving abnormally. The human body is
formed out of basic units called cells. A group of cells form tissue. Normally, cells grow
and divide to produce more cells when the body needs them. Sometimes, however, cell
growth becomes abnormal and ends up forming too many cells without control or order,
creating a mass of excess tissue called a tumour. These tumours can be classified as
benign (non-cancerous) and malignant or neoplasm (cancerous). When normal cells are
damaged beyond repair, they are eliminated by a process known as apoptosis. Cancer cells
are formed when the damaged cells avoid apoptosis and continue to multiply in an
unregulated manner (see Fig. 2.1).
(Courtesy of http://en.wikipedia.org/wiki/Cancer, 15/06/2006)
Figure 2.1: The process of normal cell growth and formation of a tumour.
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Most cancers are named after the organ they are associated with like lung cancer for cancer
that originated in the lungs, breast cancer for cancer originating from the breast and skin
originating cancer also known as melanoma. When the cancer cells migrate to another
organ, the new cells take the name of the old. For example, if lung cancer migrates to the
liver and causes cancer, then the new cancer is called metastasis lung cancer.
2.2. CANCER AND ITS IMPACT
The American Cancer Society estimates that 1,399,790 people (720,280 men and 679,510
women) will be diagnosed with and 564,830 people will die of cancer of all sites in 2006. 1
Approximately 12.5 million new cases are reported to have been diagnosed each year and
considerable research is underway to obtain a drug that can function as a vaccine against
cancer or that will cure and kill cancer cells. In the USA and other developed countries,
cancer is presently responsible for about 25% of all deaths.2
The word carcinoma is the medical term for a malignant tumour derived from epithelial
cells. It is translated from carcinos (Latin), also meaning crab. Galen used "oncos" to
describe all tumours, the root for the modem word oncology.3
Most cancers can be treated and some cured, depending on the specific type, location and
stage when it was diagnosed. Cancer is usually treated with a combination of surgery,
chemotherapy and radiotherapy. As research develops, available treatments are becoming
more specific for the type of cancer pathology. Drugs that target specific cancers already
exist for many cancers. If untreated, cancers may eventually cause illness and death,
though this is not always the case.
According to information obtained from the National Cancer Institute (NCI) website on 7
November 2006, the most common cancer types are:
Bladder cancer, Breast cancer, Colon and Rectal cancer, Endometrial cancer,
Kidney (Renal cell), Leukaemia cancer, Lung cancer, Melanoma cancer, Non-
Hodgkin's Lymphoma cancer, Pancreatic cancer, Prostate cancer, Skin (non-
melanoma) cancer, Thyroid cancer and Ovarian cancer.
5
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2.3. PLANTS AS SOURCES OF ANTICANCER DRUGS
Most of the research to discover and develop new anticancer drugs to be used for therapy is
focused on the investigation of natural resources based on the indigenous plants used for
folk medicine. Other resources include biological marine resources like sea sponges. The
NCI records show that most of the important drugs came from plant origin and this is
supported by the published anticancer agents namely, the vinca alkaloids (vinblastine and
vincristine) isolated from Catharanthus roseus, the semi-synthetic derivatives teniposide
and etoposide, from podophyllotoxin, taxol (or paclitaxel) and camptothecins.4 The great
majority of these compounds isolated from plants never made it to clinical trials or failed at
the very early stages of the trials because of cytotoxicity towards the host cells or the loss
of potency in vivo. In order to eliminate these unwanted effects of the compounds,
synthetic chemists do structural modifications by changing or introducing new
functionalities in the molecules. This process of structure activity relationships (SAR) is
aimed at improving the activity of the compound but at the same time reducing the toxicity
level.
At the present moment significant progress has been made in the research aimed at
establishing therapeutic cancer vaccines that can reliably and consistently induce tumour
destruction or improve patient survival.5 Evidence was also obtained that patients get
improved antitumour immune responses when using cancer vaccines, inducing cancer
regression or increased survival.
The reported beneficial isolation of potential antigens from plants led to the identification
of certain classes of compounds that can be useful as anticancer agents.6 These also include
molecules that have been discovered after modifications of the natural product leads7 and
the focus will be on some important classes of compounds namely, alkaloids, diterpenoids,
triterpenoids and lignans. It is however worth noting that Mukherje et ai.s reported that
since 1955, NCI has screened more than 114 000 plant-derived extracts and it was reported
that several anticancer agents obtained from natural plants are in clinical use.9 Cragg et
ai. 1D reported that five plant-derived compounds (vincristine, vinblastine, etoposide,
teniposide and taxol) have advanced to human clinical trials but of these only taxol was
discovered in the NCI programme.
6
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2.3.1. Alkaloids
Alkaloids are nitrogen-containing compounds that are mostly in cyclic form. This class of
compounds can again be grouped into different subgroups but for the purpose of this study
they will be discussed in general.
Vinca Alkaloids
Research work conducted on the Vinca rosea extracts (also known as Catharanthus
roseus) led to the discovery of their anti-neoplastic activity. The isolation of highly active
vinblastine, vincristine, leorosine and leorosidine (2.1 to 2.4) was achieved and the
compounds were developed as commercial drugs. 10,1 I
The vinca alkaloids are useful as chemotherapeutic drugs for the treatment of the following
type of cancers: Hodgkin's disease, non-Hodgkin's lymphomas, leukaemia, renal, cervical,






R = CH 3
R=CHO
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-
COOCH3
2.3: Leurosine RI = CH3
2.4: Leurosidine RI = CHO
Ukrain
A recent systematic review was conducted on the pharmacological activity and clinical
effectiveness of a chelated benzophenanthridine alkaloid known as ukrain, a semi-synthetic
compound derived from chelidonine (2.5) isolated from the extract of the common weed
Chelidonium majus L. Ukrain is a compound that is formed from thiophosphoric acid







Ukrain has been reported as the only known product which at present does not harm
normal cells but reduces the cancer cells and boosts the immune system. 13 Clinical trials
have shown that this compound has curative effects on a range of cancers.
8
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2.3.2. Campothecin and analogues
Campothecin (CPT, 2.6) was discovered in the early 1960s as an anticancer agent which
inhibits the DNA topoisomerase I in vitro as well as mouse leukaemia cells, colon and
pancreatic cancer. 14 It was first extracted from the stem wood of the Chinese tree





The two synthetic analogues of CPT (2.6), topotecan, (2.7) and irinotecan (2.8) are used
for the treatment of breast, liver, prostate, ovarian, pancreatic and colon cancers under the
label of Glaxo-SmithKline and Pfizer as Hycamtin and Camptosar respectively. 17,18
9
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2.3.3. Taxol and analogues
Paclitaxel (2.9), also known by the generic name taxol, is a complex polyoxygenated
diterpenoid isolated from Taxus brevijolia. 19 This compound and derivatives thereof were






Taxol was reported to have shown promising results in phase I and phase II clinical trials
in lung, ovarian and breast cancers and squamous cell carcinoma of the head and neck. The
FDA gave approval in 1992 to the NeI for developing and using taxol to treat metastasis
ovarian cancer but bioavailability of the drug still presents a challenge.2o The
bioavailability problem is caused by the drugs partial solubility in water. Synthetic
modifications prepared, solved this problem and a semi-synthetic derivative taxotere
(docetaxel) 2.10 was reported to show improved pharmacology compared to taxol.21 ,22
2.3.4. Lignans and analogues
Lignans are a large group of natural products that are formed by the coupling of two C6-C3
arylpropyl units. 23 There are two major lignans that are found in most plants especially
those that are edible. These lignans, secoisolariresinol (2.11) and matairesinol (2.12), get
transformed by bacterial action into mammalian lignans enterodiol (2.13) and
enterolactone (2.14), respectively (Scheme 2.1). These mammalian lignans are believed to
help stop the onset of breast and prostate cancers.24 Matairesinol (2.12) is also a precursor
in the formation of the podophyllotoxin (2.15).15
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2.12: Matairesinol 2.14: Enterolactone
Scheme 2.1: The major lignans and their bacterial-converted mammalian intermediates.
Podophyllotoxin (2.15) and desoxypodophyllotoxin (2.16) are well-known natural
aryltetralin lignans and the former was isolated from Podophyllum species, but initially
from P. emodi. The natural derivative desoxypodophyllotoxin was isolated from
Anthriscus sylvestris and Pulsatilla koreana.26
Both of these compounds show cytotoxic effects against cancer cell lines and their semi-
synthetic derivatives etoposide (2.17) and teniposide (2.18) are in use as chemotherapeutic
agents against various cancers.27 Etoposide is the most widely-used anticancer agent and
the NeI database records its use mainly for the treatment of leukaemia.28
There are other semi-synthetic analogues of podophyllotoxin that were prepared and
exhibited anticancer activity against numerous cancer cells. Most of these compounds
failed because of their non-specific toxicity to both normal and cancer cells, as well as
bioavailability problems. These compounds also show antiviral29,3o and anti-HIV
activities. 31
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Another plant-derived lupane type triterpenoid, betulinic acid (2.19) has been isolated from
many taxonomically diverse plant genera and it demonstrated a variety of activities like
antibacterial, anti-inflammatory, antimalarial, inhibition of HIV replication and
cytotoxicity against a range of cancer cell lines. 32
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Two well-known triterpenoids, ursolic acid (2.20) and oleanolic acid (2.21), are said to be
associated with weak anti-inflammatory and antitumour activities. Attempts to prepare
synthetic analogues in order to improve the potency led to the synthesis of 2-cyano-3,12-
dioxo-olean-I,9-dien-28-oic acid (CDDO, 2.22), which exhibited potent in vitro and in
vivo anticancer activity against epithelial ovarian carcinoma cell lines. 33
Compounds developed from natural products in the 1990s like vinblastine, vincristine,
combretastatin and maytansine exert their action through the depolymerization oftubulin.6
Taxanes stabilize against depolymerization whereas camptothecin derivatives like











2.21: Oleanolic acid 2.22: CDDO
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2.4. INTRODUCTION TO ERECTILE DYSFUNCTIONILIBIDO
Sexual dysfunction (SD) is a clinical problem that affects both males and females. The
causes thereof may be both organic and psychological. Organic aspects of SD are typically
caused by underlying vascular diseases such as those associated with hypertension or
diabetes mellitus, prescription medication and psychiatric disease such as depression.
Physiological factors include fear, performance anxiety and interpersonal conflict. SD
impairs sexual performance, diminishes self-esteem and disrupts personal relationships
thereby inducing personal distress. In the clinic, SD disorders have been divided into
female sexual dysfunction (FSD) disorders and male sexual dysfunction (MSD)
disorders.34
FSD is best defined as the difficulty or inability of a woman to find satisfaction in sexual
expression which can be related as libido. Male sexual dysfunction (MSD) is generally
associated with erectile dysfunction, also known as male erectile dysfunction (ED).35
Erectile dysfunction has been defined as the repeated inability to achieve or sustain an
erection for sexual performances. ED affects the lives of over 150 million men
worldwide.36 Most underlying factors that contributes to the onset of ED includes
conditions like stress, diseases (e.g. diabetes) and blocking of penile arteries from the side
effects of some prescription drugs.
Penile erection is a carefully orchestrated series of events with the central nervous system
in the role of conductor. Even when the penis is at rest, the nervous system is at work.
When a man is at rest, part of the sympathetic nervous system limits the flow of blood to
the penis, keeping it limp. Regardless of where the stimulant signals come from, the
excitory nerves in the penis respond by releasing the pro-erectile neurotransmitters such as
nitric oxide (NO) and acetylcholine. These chemical messengers signal the muscles of the
penile arteries to relax causing more blood to flow into the organ. Spongy chambers inside
the penis fill up with blood causing the erection and consequently compress the veins that
drain the blood.
14
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2.5. THE COMMERCIAL PRODUCT VIAGRA
The commercial product Viagra (2.23) also known as sildenafil, works by slowing the
breakdown of one of the chemicals that keeps the muscles relaxed, thereby holding the
blood in the penis for a longer period (see flow diagram in Fig. 2.2).
2.23: Sildenafil R = CH3
2.24: Vardenafil R = CH2CH3
2.25: Tadalafil
Viagra was developed in 1998 by Pfizer as the first synthetic oral drug treatment for male
ED. Sildenafil is a potent inhibitor of the phosphodiesterase 5 (PDE 5) enzyme.37,38 This
compound acts by triggering the sexual stimulant that leads to the enhanced release of
nitrous oxide which is synthesized via the non-adrenergic non-cholinergic (NANC) nerve
and endothelial cells. NO activates the enzyme guanilate cyclase that Increases the
intracellular concentration of cyclic guanosine 3' ,5' -monophosphate (cGMP) by
conversion from guanosine triphosphate (GTP). The increase in cGMP concentration
causes a decrease in intracellular Ca2+ levels in the corpus cavernous smooth muscle
followed by relaxation of the smooth muscle. During this process in the corpus carvenosa,
some of the cGMP is hydrolysed to 5'-guanosine monophosphate (GMP) by the PDE 5
enzyme. Thus, sildenafil and its analogues act by limiting the hydrolysis of cGMP to GMP
through selective inhibition of the PDE 5 enzyme39,40 and thereby increasing the
intracellular concentrations of cGMP and facilitating corpus cavernous smooth muscle
relaxation. It is now understood that sildenafil citrate is an effective and safe inhibitor of
phosphodiesterase 5, the predominant isoenzyme in the human corpus cavernosum.
15
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Decreased levels of phosphodiesterase allow increased production of nitrous oxide which,












Figure 2.2: Pathway leading to penile erection.
Sildenafil has been reported to be 10 fold less effective at the same concentrations as
compared to the corresponding synthetic analogues, Vardenafil ( Levitra, 2.24) and
Tadalafil (Cialis, 2.25).41
2.6. NATURAL TREATMENTS OF ERECTILE DYSFUNCTION
The introduction of Viagra and other synthetic analogues presented a solution for the ED
problem but these compounds also present some side effects. There is thus a necessity to
develop a product with fewer side effects. Researchers are still focusing on the research in
natural products and specifically in the plant kingdom. There have been several reports
documenting the use of extracts made from herbal products for the treatment of ED. A
review of plant-derived compounds used for ED was published by Drewes et al.42
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Plants and their active components, reported to be used for the treatment of erectile





Saw palmetto (Serenoa repens)
Ptychopetalum olacoides also known by the common name Muira puama
Papaver somniferum contains papaverine42
Papaverine
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Coptis chinensis which contains berberine
Berberine
Eriosema kraussianum which contains the pyranoisoflavone kraussianone
Kraussianone
Pausinystalia yohimbe Pierre (fonnerly Corynanthe yohimbe) containing yohimbine, an
alkaloid.42
Yohimbine
Most of these products act by the same mechanism as the synthetic sildenafil although this
is not the only mechanistic orchestration of events that can lead to the onset of the
concomitant treatment of ED. For the purpose of this study only the route that follows the
inhibition of the PDE 5 was studied.
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General materials and methods that were used in some or all subprojects are described here
in order to avoid repetitions. However, specific materials and methods used in this study
are described in the corresponding chapters.
3.1. PLANT COLLECTION
The plants were collected as part of a collaborative initiative of the CSIR with the National
Cancer Institute of the United States (NCI) to evaluate South African plants for anticancer
properties against a panel of cancer cell lines hosted at the CSIR and the NCT. The source
of the plant material was either from the Traditional Healers Committee (THC) who has a
vast knowledge of indigenous plant use or botanists who collected plants at random. The
collections were made all over South Africa based on the availability of the plant material
for collection. Plant specimens were sent to the South African National Biodiversity
Institute (SABNI) in Pretoria for identification.
3.2. PROCESSING AND EXTRACTION OF PLANT MATERIAL
The plant material was temporarily stored in a cold room maintained at 4 QC until further
processing. The plants (roots and/or stems and/or leaves) were weighed, dried in the oven
maintained at 45 QC long enough to achieve proper drying. The drying process was
monitored every 24 hours and resulted in at most 3 days of drying period. Grinding of
oven-dried plant material was done at the CSIR using a hammer mill equipped with a mesh
pore size of 2 mm. The dried, ground plant material was then subjected to exhaustive
extraction as outlined in the flow diagram (Fig 3.1).
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3.2.1. Extraction
Aqueous extraction
For aqueous extractions, one of two routes was followed (see Fig. 3.1).
(A) Route 1
The dried material was first extracted with deionised water, enough to cover the plant
material. The mixture was stirred occasionally for 4 h and then filtered. The aqueous
filtrate was freeze-dried and the remaining plant material was placed in an oven for drying
to prepare the material for the organic solvent extraction.
(B) Route 2
The dried, ground plant material was extracted in the extraction vessel by adding enough
deionised water to cover the plants. The mixture was boiled for an hour as per the
traditional method of preparation of herbal medicines. The cooled extract was filtered and
the filtrate was freeze-dried. The plant residues were discarded.
Choose path according to traditional
or pharmaceutical preparations






1. Split material into 4:6 ratio for
Methanol-Dichloromethane and
Water extraction
Figure 3.1: Flow diagram of the general extraction process
Organic extraction
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The protocol followed for the organic solvent extraction was the same for both routes but
the pathway leading to their preparation was different.
The oven-dried, ground plant material was transferred to the extraction vessel. Sufficient
organic solvent [methanol-dichloromethane Cl: 1 v/v)] was added to cover the plant
material. The extraction mixture was left to stand for four to twenty four hours with
occasional stirring. The solvent was filtered off and evaporated under reduced pressure at a
temperature of not more that 60 Qc. The extract was transferred to a tared sample bottle
and the residual plant material was discarded.
3.2.2. Liquid-liquid partitioning
The general separation procedure accomplished by liquid-liquid partitioning involved the
partitioning of the organic extract (refer to section 3.2.1.) between methanol-water (90%,
v/v) and hexane three times in a separating funnel. The hexane layers were combined and
evaporated under reduced pressure and the aqueous residue was diluted with water,
concentrated by evaporation of the methanol under reduced pressure and extracted three
times with dichloromethane. The combined dichloromethane layers were evaporated under
reduced pressure. The water layer was concentrated by evaporating under vacuum and
thereafter it was subjected to freeze-drying. The schematic diagram in Fig. 3.2 illustrates
the extraction procedure.
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1. Stir in Methanol-Dichloromethane (1:1, vlv)
2. Filtration
Evaporate the solvent
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2. Separate the two layers
Evaporate the solvent
I' Aqueous methanol 1
1. Concentrate the aqueous solution
2. Add more water
3. Dichloromethane-Water(1:1, vlv)
partitioning
4. Separate the two layers
Evaporate the solvent




Thin-layer chromatography (TLC) was carried out using either aluminium base sheets
covered with silica gel 60 F254 (Merck 5554) or pre-coated glass plates (Merck, SIL 0-25
UV254, 0.25 mm, 20 x 20 cm). Standard chromatograms of plant extracts and isolates were
prepared by applying a concentrated sample to a silica gel TLC plate and developing it
with suitable solvent combinations. Chromatograms were detected using ultraviolet (UV)
light (short wave 254 nm and long wave 366 nm). The general TLC spraying reagent used
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was vanillin-H2S04 reagent (l g vanillin dissolved in 100 ml of 85% H2S04) and the
sprayed TLC plate was heated at 100 QC for a few minutes.
3.3.2. High Performance Liquid Chromatography (HPLC) and detectors (DV-MS)
HPLC-DV-MS experiments were performed on a Waters 2690 Alliance HPLC Separations
Module, linked to a Waters 996 Photo Diode Array detector (PDA) and interfaced to a
triple pole Quattro LC Micro mass spectrometer. The mass spectrometer was operated in
the positive or negative mode using electrospray ionisation (EStl-). Chromatography was
performed on an aDS Hypersil C18 (5 Jlm) HPLC column (250 x 4.6 mm) equipped with
a Hypersil C18, 5 Jlm guard column. Typical eluting solvents were acetonitrile-water in a
gradient system at a flow rate of 1 ml/min. The column temperature was set at 40 QC and
the solvents were pre-filtered through a 0.45 Jlm filtering membrane.
If not stated otherwise, analyte sample concentrations of between 2500 and 5000 ppm (i.e.
1.0 - 5.0 mg/ml) were prepared by dissolving the sample in the appropriate elution solvent.
Injected amounts usually equalled 20 Jll of extract solution per acquisition. The samples
were manually filtered through a 0.45 Jlm filtering disk before feeding into the auto
sampler for injection through a column. The flow was split after the column to the variable
PDA DV detector and the mass spectrometer at a ratio of 15:1 respectively.
3.3.3. GCIMS
GC/MS was performed on an Agilent (Hewlett Packard) HP 6890/5973 GC/MSD
instrument equipped with a fused silica capillary column, film (5% phenyl methyl silicone)
thickness 0.25 Jlm and data processed using an HP computer with a Wiley 138.1 library for
companson.
3.3.4. VLC and CC
Sorbents for vacuum liquid chromatography (VLC) and column chromatography (CC)
were either silica gel 60 normal grade (0.063-0.200 mm Merck 70 - 230 mesh) or flash
grade (0.040 - 0.063, Merck 230 - 400). Chromatography was performed with CP grade
solvents.
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3.4. STRUCTURE ELUCIDATION
3.4.1. NMR Spectroscopy
NMR spectra were recorded on either a Varian Unity 400 MHz spectrometer or a Varian
Unity Inova 500 MHz spectrometer operating at 400 and 500 MHz for IH and 100 and 125
MHz for l3C using standard pulse programs. The internal reference standard used was
tetramethylsilane (TMS). Spectra were obtained for solutions in deuterium solvents.
Multiplicity for l3C was deduced from DEPT experiments; s = C, d = CH, t = CH2, q =
CH3. Structural assignments were based on spectra resulting from one or more of the
following NMR experiments: IH, l3C, DEPT, IH_1H COSY, IH_l3C direct correlation
(HMQC), IH_ 13C long-range correlation (HMBC) and IH difference NOE.
3.4.2. Mass Spectrometry
Mass spectral data was obtained on a GC-ElMS (70 eV) at the CSIR laboratories in the
Biosciences platform. FABMS was obtained from a Micromass Model AutoSpec ETOF
El+ (70 eV) spectrometer at North West University (Potchefstroom). HREIMS were
obtained from the University of the Witwatersrand using a Model VG 705EQ operating in
positive El mode.
3.4.3. Optical Rotation
Optical rotations were measured using a Perkin Elmer 241 Polarimeter equipped with a 1
mL cell, cell length 10.000 cm. Rotations were recorded using the Na lamp at 589 nm.
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3.5. DESCRIPTION OF BIOLOGICAL ASSAYS
3.5.1. In vitro anticancer screen
Assay Laboratory: CSIR Biosciences, Bioprospecting Platform, Pretoria (RSA)
Methodology
The anticancer screening programme at the CSIR housing three cell lines was initiated as a
collaborative project with the National Cancer Institute (NCI) in the USA aimed at the
discovery of new anticancer drugs. The protocol used for the anticancer screening at CSIR
was successfully transferred from the NCI and the cancer cell lines were provided by the
NCI under the collaborative agreement.
The three cell line pre-screening method was used in the testing of the extracts and the
compounds that were isolated from the extracts. Extracts were initially screened at the
CSIR at a single dose (100 IJ,g/ml concentration) to determine their anticancer activity
against the three cell lines viz. MCF7 (breast), TKIO (renal), and UACC62 (melanoma).
Extracts that exhibited a growth inhibition of above 75% for two or three cell lines were
subjected to further screening at five serial dilution concentrations. The results obtained
from this test were presented as dose-response curves (Fig. 3.3) for each cell line.
The dose-response curve is a plot of the percent growth inhibition (GI) of the cancerous
cells against the concentration of the extract or the compound presented in parts per million
(ppm or Jlg/ml). The response parameters were interpolated values from these graphs
representing the concentrations at which the GI was +50, 0, or -50 respectively interpreted
as fifty percent growth inhibition (GIso), total growth inhibition (TGI) and the fifty percent
lethal concentration (LCso).
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Figure 3.3: Typical graph representing the plotted anticancer screen results





= TGI (Total Growth Inhibition) > 50 ppm
= TGI between 15 ppm and 50 ppm for two or three cell lines
= TGI between 6.25 ppm and 15 ppm for two or three cell lines
= TGI < 6.25 ppm for two or three cell lines
3.5.2. In vitro 60 cell lines anticancer screen 1,2,3
Assay Laboratory: National Cancer Institute (NCI) in the USA
The screening was a two-stage process, beginning with the evaluation of all extracts or
compounds against the 60 cell lines at a single dose of 100 ppm or 100 ~M. The output
from the single dose screen was reported as a mean graph. Compounds and extracts which
exhibit significant growth inhibition were evaluated against the 60 cell panel at five
concentration levels.
Selected plant extracts and compounds that showed some cytotoxicity against the three
cancer cell lines at CSIR preliminary screen were assayed by the NCI against their 60
cancerous cell lines. The panel of cancer cell lines includes sub-cells from leukaemia (6),
non-small lung cell (NSLC, 8), colon (6), CNS (4), melanoma (8), ovarian (6), renal (7),
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prostate (2) and breast (6) (the values in brackets are the number of sub-cells in each cell
line). A statistical programme was used to obtain the log GIso value (logarithm of the
concentration at 50% growth inhibition) to categorize the resulting anticancer activity as
interpreted by the NCI.
Methodology
The protocol used by the NCI to screen the compounds and extracts is the same as the one
adopted by the CSIR and it has been published in scientific papers4,S,6 and the protocol can
also be obtained from the NCI website.
Using the absorbance measurements time zero (Tz), control growth, (C), the percentage
growth was calculated at each of the drug concentration levels. Three dose-response
parameters were calculated for each experimental agent. Growth inhibition of 50 % (GIso)
was calculated as a concentration where 50% of the net protein increase is reduced (as
measured by SRB staining) in control cells during the drug incubation. The drug
concentration resulting in total growth inhibition (TGI) was also calculated. The LCso
(concentration of drug resulting in a 50% reduction in the measured protein at the end of
the drug treatment as compared to that at the beginning) indicating a net loss of cells
following treatment was calculated equal to -50. Values were calculated for each of these
three parameters if the level of activity was reached; however, if the effect was not reached
or was exceeded, the value for that parameter was expressed as greater or less than the
maximum or minimum concentration tested. Significant potency was considered for at




= log GIso between 1.10 ppm and 1.50 ppm
= log GIso between 0.00 ppm and 1.10 ppm
= log GIso < 0.00 ppm
The extracts that showed weak to potent inhibition of cancerous cell growth were
fractionated to isolate the compounds responsible for the activity. The compounds were
also assayed at five different concentrations. The results obtained from this test were
presented as dose-response curves for each cell line.
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3.5.3. In vitro cytotoxicity assay against a mammalian cell line, Chinese Hamster
Ovarian cells (CHO)
Assay Laboratory: Department of Medicine, Division of Pharmacology, University of
Cape Town (RSA)
Methodology
The samples were tested for in vitro cytotoxicity against a mammalian cell line, Chinese
hamster ovanan cells (CHO), usmg the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay. All samples were tested in triplicate in a single
experiment. The MTT-assay was used as a colorimetric assay for cellular growth and
survival and compares well with other available assays.7,8 The tetrazolium salt MTT was
used to measure all growth and chemosensitivity.
Aqueous samples were dissolved in water and orgamc samples were dissolved in
methanol-water (1 :9). The samples that did not dissolve completely or formed a suspension
were dissolved in DMSO. The samples that did not dissolve even when using DMSO were
tested as a suspension. The initial concentration of stock solutions was 2 mg/ml for all
samples. Samples were stored at -20 QC until use. The highest concentration of methanol to
which the cells were exposed to had no measurable effect on the cell viability (data not
shown). Emetine was used as the positive control in all experiments. The initial
concentration of emetine was 100 f.lg/ml, which was serially diluted in complete medium
with ID-fold dilutions to give 6 concentrations, the lowest being 0.001 f.lg/ml. The same
dilution technique was applied to all other samples with an initial concentration of 100
f.lg/ml to give 5 concentrations, with the lowest concentration being 0.010 f.lg/ml.
The 50% inhibitory concentration (ICso) values for these samples were obtained from dose-
response curves, using a non-linear dose-response curve fitting analyses via Graph Pad
Prism v.2.01 software.
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3.5.4. Antibacterial screen
Assay Laboratory: University of Pretoria, Pharmacology department, South Africa
Methodology
The crude extracts supplied were re-suspended to a known concentration of 20 mg/ml. The
extract was suspended in a small amount of DMSO and made up to the desired
concentration with water.
The test orgamsms III the investigations of antibacterial activity included two Gram-
positive bacteria, Enterococcus faecalis and Staphylococcus aureus, and two Gram-
negative species, Pseudomonas aeruginosa and Escherichia coli. A micro plate serial
dilution method9 was used to evaluate the antibacterial activity of extracts. This method
allows the calculation of minimal inhibitory concentration (MIC) values for active plant
extracts against each bacterial species. A two-fold serial dilution of plant extract was
prepared in 96-well micro titre plates and bacterial culture was added to each well. The
presence of bacterial growth was detected by the addition of a tetrazolium salt, which was
reduced to a red-coloured formazan by biologically active organisms; in this case the
dividing bacteria. When the solution in the well remains clear after addition of the extract,
bacterial growth was inhibited by that concentration of plant extract. Neomycin was used
as a positive antibiotic control and appropriate negative solvent controls were included.
In order to establish the possible compounds responsible for the inhibition of bacterial
growth, the components of the sample were separated by TLC using ethyl
acetate:methanol:water [45:5:4.4] [EMW] as solvent system.
Bioautography was performed as a supplementary qualitative analysis for the presence of
antibacterial compounds. After the diffusion of the eluent at room temperature, the TLC
plate was sprayed with a suspension of S. aureus. After overnight incubation, the plate was
sprayed with a tetrazolium salt to identify the presence of antibacterial compounds in the
samples. The active compounds appeared as white spots (no bacterial growth) on a pink
background of dividing bacteria.
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3.5.5. Rabbit corpus cavernosum smooth muscle relaxation / contraction assay
Assay Laboratory 1: University of Pretoria, South Africa
Methodology
The bioassay was performed as described by Levin et al. lo with some minor changes.
Strips (12 mm long and 1-2 mm thick) of rabbit corpus cavernosum smooth muscle were
dissected and mounted in an organ-bath chamber containing Krebs-PSS solution with the
following composition: NaCI = 7.01 g/l, KCI = 0.34 g/l, KH2P04 = 0.1 g/l, NaHC03 = 1.99
g/l, CaCh = 0.2 g/l, MgS04 = 0.3 g/l and glucose = 1.8 g/l. One end of the muscle was tied
to the inside bottom of the perfusion bath and the other end to a thin wire connected to a
Harvard isotonic force transducer for isotonic tension measurements. Changes in isotonic
tension were recorded on a computerized calibrating program. The corpus cavernosum
muscle was perfused with 2ml Krebs-PSS buffered saline and oxygenated with 95% O2
and 5% C02 for 5 min to ascertain a stable baseline recording. This was followed by
perfusion with 2 ml of CaCh in Krebs-PSS (17.8 mg/ml) for muscle contraction. Baseline
tension was set at the point of maximal contraction following the addition of CaCh into the
experimental bath. The extracts to be analyzed were added after a stable contraction
baseline. The same procedure (and concentration) was repeated for the positive control,
Sildenafil. The contraction/relaxation was reported relative to sildenafil (Viagra) tested at
78 ng/ml. In these experiments the stimulation frequency used for rabbit strips was 9 Hz.
Assay Laboratory 2: MDS Pharma, Taiwan
Methodology
Corpus cavernosum obtained from New Zealand-derived albino male rabbits weighing 2.5
- 3.0 kg and sacrificed by C02 overexposure was used. A strip from the basal area of the
corpus cavernosum was removed and placed under 2 g tension in a 10 ml bath containing
Krebs solution pH 7.4 at 32 DC and sub-maximal isometrically recorded tonic contraction
was induced by phenylephrine (3 IJM). Test substance (30 IJM)-induced relaxation by 50
percent or more (~50%) within 5 minutes, relative to the control 0.3 IJM sodium
nitroprusside response, indicates significant relaxation.
33











*Indicates standard reference agent used.
The method used is cited also in publications by Angulo et al. 11 and Thompson et aI. l2 .
3.5.6. Phosphodiesterase 5 enzyme (PDE5) inhibition assay
Assay Laboratory: MDS Pharma, Taiwan
Methodology
PDE5 partially purified from human platelets was used. Test compound and/or vehicle
were incubated with 3.5 J..I.g enzyme# and 1 J..I.M cGMP containing 0.01 J..I.M eH]cGMP in
Tris buffer pH 7.5 for 20 minutes at 30 Qc. The reaction was terminated by boiling for 2
minutes and the resulting GMP is converted to guanosine by addition of 10 mg/ml snake
venom nucleotidase and further incubation at 30 QC for 10 minutes. Unhydrolyzed cGMP
is bound to AG l-X2 resin and remaining eH]guanosine in the aqueous phase is quantitated
by scintillation counting. Compounds were screened at 100 J..I.M.















*Indicates standard reference agent used.
The method is also published in Hidaka et al. l3 and Nicholsen at al. 14.
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Phylica paniculata Willd. (Fig. 4.1) is a perennial shrub or small tree with grey-green
foliage that occurs on moist slopes and bush and forest margins.2 It can be easily confused
with P. buxifolia because of the type of leaves and flowers that are cream and aromatic
(compare in Fig. 4.1). P. buxifolia is common from the Cape Peninsula area (Table
Mountain) to Caledon and grows on mountain slopes near the sea and in rocky places. The
distribution of P. paniculata is from the Hex River valley and Wittenberg to Zimbabwe2
(Fig. 4.2).
-' ~. •... :....-;:,,"',,- .. ".'\ -
"Pictures courtesy of the Field guide to Trees of Southern Africa'"
Figure 4.2: Distribution of Phylica paniculata in Southern Africa
P. paniculata was collected by a botanist who was contracted by CSIR to collect endemic
plants at random. The crude extract inhibited the growth of cancerous cells in vitro. This
chapter reports the isolation, identification and activity of the active ingredient and another
structurally related compound.
4.1.2. Ethnopharmacology
Desktop literature studies revealed no published ethnopharmacological information on this
species and its related species.
4.2. PHYTOCHEMICAL STUDIES
A literature study did not yield any published information on the phytochemistry of P.
paniculata. Four alkaloids, reticuline (4.1), N-methylcoclaurine (4.2), lauroscholtzine (4.3)
and isocorydine (4.4), were isolated from the related species P. rogersii. 4,5 These alkaloids
38
Chapter 4: Bioassay-guided isolation and anticancer activities ofP. paniculata
have antiplatelet aggregation activity, weak neuromuscular inhibition, cardiac depressant,
antimicrobial properties and no anti-tussive activity.6
4.1: Reticuline RI = OCH3, R
2 = OH
4.2: Coclaurine RI = OH, R2 = H
4.3: Lauroscholtzine RI = OH, R2 = H
4.4: Isocorydine
From other genera of the Rhamnaceae family alkaloids, polyphenols, anthracenones,
quinones, tetracosanolides, procyanidin glycosides and triterpenoids have been isolated.
4.3. ISOLATION OF THE ACTIVE COMPOUND
Plant material of P. paniculata was collected from a farm near Marikana, Northwest
Province. The plant material was dried, ground, extracted and partitioned as indicated in
Fig. 4.3. The extract and fractions were assayed for growth inhibition of three cancer cell
lines (melanoma UACC-62, renal TK-I0, and breast MCF-7) in the CSIR laboratories.
The activity was associated with the dichloromethane fraction 4-D (Fig. 4.3) and column
chromatography of this extract yielded an active fraction labeled 4-F2. Spectroscopic
analyses of this fraction led to the identification of a pentacyclic triterpenoid ursolic acid
(4.5). This compound was isolated as a white amorphous powder with molecular formula
C30H4803
The amount of ursolic acid isolated was insufficient to conduct all spectroscopic and
experiments for the proper identification of this compound. Thus, from the same batch of
collected plants, the medium polar components were isolated following a method
summarised in Fig. 4.4. This protocol was followed because the dichloromethane fraction
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obtained by liquid-liquid partitioning in the first isolation method was selectively active.
TLC analysis confirmed that the dichloromethane extract 4-G (Fig. 4.4) contained the
same compounds as the dichloromethane fraction 4-D (Fig 4.3). The two fractions also
exhibited similar anticancer activity. Repeated column chromatography of the combined
fractions 4-D and 4-G on silica gel yielded ursolic acid (4.5) and a second pure compound,
a-amyrin (4.6).
sequential extraction
1. Stir in water for at least 4hr
2. Filter
3. Freezedry solution and dry
residual plants
4. extract with 1:1 (vlv) methanol-
dichloromethane
5. Filter
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Figure 4.3: General isolation procedure followed to isolate the bioactive compound.
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Figure 4.4: Schematic illustration of the isolation of a-amyrin and ursolic acid
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Ursolic acid (4.5) isolated from the organic extract of the leaves of Phylica paniculata was
not visible on a TLC plate under either long (360 nm) or short (254 nm) wavelength UV
light. However, after spraying the plate with vanillin spraying reagent and heating it at 100
QC for a few minutes, the compound appeared as a pink spot on a clear background.
NMR data of the compound revealed thirty resonance signals in the 13C spectrum,
suggesting that the compound could be a triterpenoid. Structural elucidation of
triterpenoids is challenging, especially to characterize the complex saturated alkyl region.
In the l3C spectrum, there is evidence for a carbonyl function (Dc 180.3), a trisubstituted
alkene (Dc 138.0 and 125.4), an oxygen-containing methine (Dc 78.8) and seven methyl
groups. In the 'H NMR spectrum, five tertiary methyl (OH 0.76, 0.74, 0.88, 0.91 and 1.01)
and two secondary methyl groups (OH 0.79 and 0.86) were identified. Correlations between
protons of two geminal methyl groups and the signal at Dc 78.8 confirmed the presence of a
hydroxyl group at C-3.
Three well-known and dominant types of triterpenoids were initially considered namely,
ursane, oleanane and lupane derivatives. A review article summarising 13C NMR data of
99 of triterpenoids7 assisted us with the assignment of the structure. Comparison with the
published data enabled the assignment of a C-28 carboxylic acid at Dc 180.3 and located
the double bond (Dc 125.4 and 138.0) between C-12 and C-13. The presence of a 29-
methyl group attached to C-19 is believed to cause deshielding of the double bond carbon
C-12 and shielding of C-13 as compared to the resonances of the oleanolic acid double
bond.8,9
From the proton spectrum, five methyl singlets (OH 0.76, 0.74, 0.88, 0.91, and 1.01) could
be assigned together with two doublets (OH 0.79, JHH= 6.0, OH 0.86, JHH = 7.0). The olefin
proton in position C-12 was assigned to a resonance signal at OH 5.08.
The structure of compound 4.5 was assigned as ursolic acid. The structure was confirmed
by comparison of the obtained NMR data with the published literature data together with
the reported MS data as well as optical rotations. 10,1 ,
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In the Et mass spectrum, a molecular ion at rn/z 456 agrees with a molecular formula
C30H4s03. The library match from the GC-MS instrument identifies ursolic acid with a
97% possibility match.
Table 4.1 : l3C (lOO MHz) and IH (400 MHz) data for ursolic acid (4.5) in CDCh +
CD30D.
Compound 4.5 Literature11 •t
C be bH (J in Hz)* be bH (Jin Hz)
I 38.6 1.16-1.51 (m,2H) 39.2 1.00-1.58
2 28.6 1.85 (m,2H) 28.2 1.81
3 78.7 3.12 (m,IH) 78.2 3.44 (dd)
4 38.5 39.6
5 55.1 0.87 (m,IH) 55.9 0.88 (d)
6 18.2 18.8 1.58-1.39
7 32.9 33.7 1.59-1.39
8 39.3 40.1
9 47.4 48.1 1.65
10 36.8 37.5
II 23.1 23.7 1.96
12 125.4 5.18 (s, broad,IH) 125.7 5.49 (s)
13 138.0 139.3
14 41.9 42.6
15 29.5 28.8 1.22-2.33
16 24.1 25.0 2.14-2.01
17 47.7 48.1
18 52.7 2.12(d,IH,J=11.2) 53.6 2.63 (d)
19 38.9 39.5 1.49
20 38.7 39.4 1.05
21 30.5 31.1 1.40-1.49
22 36.7 37.4 1.97
23 27.9 0.91 (s,3H)* 28.8 1.24 (s)
24 15.2 0.74 (s, 3H)* 16.5 1.02 (s)
25 15.4 0.70 (s, 3H)* 15.7 0.92 (s)
26 16.7 0.87 (s, 3H)* 17.5 1.06 (s)
27 23.3 1.01 (s,3H)* 24.0 1.24 (s)
28 180.3 179.7
29 16.8 0.85 (d, 3H, J= 5.9) 17.5 1.02 (d)
30 21.0 0.79 (d, 3H, J= 6.3) 21.4 0.97 (d)
t The experiments were done at 313 K with compounds dissolved in pyridine-ds
* The assignments of the methyl signals can be interchanged.
There have been a number of reassignments of the carbon signals of this compound since
its early characterizationl2,13 but assignments were recently confirmed by 2D NMR
experiments (see Table 4.1). It was also cited that the resonance assignments of this
compound has been revised as the l3C shifts for C-24/C-25 are interchanged. 10
43
Chapter 4: Bioassay-guided isolation and anticancer activities ofP. paniculata







This triterpenoid showed a single spot on TLC in various solvent systems but with an Rf
value in close proximity to that of ursolic acid. In the 13C NMR spectrum of compound 4.6,
30 resonances were observed. A closer inspection of the data showed the 13C data to be
similar to that of ursolic acid (4.5). The main difference is the absence of the carboxylic
acid resonance peak at Oc 180 (C-28). Inspection of the spectral data pointed to the
substitution of the C-19 carboxylic group with a methyl group (oc 28.2). Two signals at Oc
126.0 and 138.1 were assigned to olefinic carbons.
As with ursolic acid (4.5), compound 4.6 gave 2 doublet methyl signals OH 0.75 and OH
0.87 assigned to C-29 and C-30, respectively. The chemical shifts observed for C-12 and
C-13 are in agreement with an urs-12-ene skeletal structure. Singlet signals representing
three protons each were identified upfield from TMS signal at OH 0.95, 0.74, 0.75, 1.04,
1.21, 0.89, 0.82 (J = 6.3 Hz) and 0.91 (J = 6.3 Hz) for respective positions C-23 to C-30
that were assigned to the methyl protons in a quaternary environment.
The structure of compound 4.6 was assigned as a-amyrin. The Et mass spectrum of the
compound shows a molecular ion peak at m/z 426, which supported the molecular formula
of C30HsoO. Comparison with the I3C NMR of uvaol
7 (28-hydroxy-a-amyrin) led to the
suggested structure of compound 4.6.
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Table 4.2: l3C (lOO MHz) and IH (400 MHz) data for a-amyrin (4.6) in CDCl].
Compound 4.6 (a-amyrin) LiteratureI4.IS.16
C bc bH (Jin Hz) bc bH (J in Hz)
1 38.9 38.7
2 27.2 27.2




















23 28.3 0.95 (s) 28.1 0.99 (s)
24 15.6 0.74 (s) 15.6 0.79(s)
25 15.7 0.75 (s) 15.6 0.95 (s)
26 17.1 1.04 (s) 16.8 1.0 I (s)
27 23.4 1.21 (s) 23.2 1.07 (s)
28 28.2 0.89 (s) 28.1 0.84 (s)
29 17.2 0.82 (d, J =6.3) 17.4 0.79 (d, J= 5.5)
30 21.3 0.91 (d,J=6.3) 21.3 0.91 (d, J= 5.5)
The IH NMR spectra data showed a doublet of a doublet at OH 3.18 which was assigned to
the proton attached to position 3 adjacent to the hydroxyl group. The splitting pattern
(doublet of a doublet) resulted from the interaction between the diastereotopic protons in
position 2, one situated in the alpha and the other in the beta position. The coupling
constants observed for H-3 (J = 10.7 and 5.6 Hz) confirms the axial orientation of this
proton and the p-orientation of the 3-hydroxyl group.
A triplet resonance signal (OH 5.08, t, J= 3.5 Hz) was assigned to the C-12 protons which is
characteristic of the coupling observed between a proton on C-12 and the methylene
protons on the sp3-hybridised C-Il.
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4.3.3. Analysis of plant extracts and primary fractions by liquid chromatography.
The crude extracts were analysed by HPLC with the pump gradient starting with 90: 10
water-acetonitrile and changing gradually to 100% of acetonitrile after 75 minutes. The
water fraction (Fig 4.5) managed to extract most of the highly polar compounds with a
retention time of less than 15 minutes where the solvent gradient was still predominately
water. The dichloromethane extracted most of the compounds in the mid-polar region.
There was one distinct major peak at 62.79 minutes that still remains to be identified. This
peak representing an unidentified compound was selectively extracted by dichloromethane.
Apart from this compound there were several other peaks which are representative of the
minor compounds. Lastly, after 60 minutes when the solvent was almost 100% organic, the
least polar compounds were detected.
At a glance it was concluded that the attempt to separate the organic extract into three
fractions containing compounds of different polarity was a success. The DV fingerprint of
the methanol-dichloromethane extract is a total representative of the fractions obtained
from the partitioning as a means of primary fractionation.
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Figure 4.5: Le-DAD chromatograms of the organic methanol-dichloromethane extract
prepared of the whole plant and of the fractions obtained for the liquid-liquid partitioning
using hexane, dichloromethane and water.
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Figure 4.5. Continued: Le-DAD chromatograms of the organic methanol-
dichloromethane extract prepared of the whole plant and of the fractions obtained for the
liquid-liquid partitioning using hexane, dichloromethane and water.
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4.4. BIOLOGICAL ACTIVITY
The plant extract and the compounds obtained were tested for anticancer activity against
three highly sensitive cell lines viz. melanoma UACC-62, renal TK-lO, and breast MCF-7
in the CSIR laboratories.
Extracts of the whole plant were prepared as shown in Fig 4.3. Sequential extraction
yielded an aqueous extract 4-A and a methanol-dichloromethane extract 4-B. These
extracts were tested for anticancer activity at a single dose concentration (100 Ilg/ml) and
only the organic extract showed a noteworthy inhibition of the growth of cancerous cells.
The results obtained from the CSIR laboratories were confirmed by the National Cancer
Institute (NCI) who obtained a weak activity (log GIso = 1.33 Ilg/ml) for the extract with
no selectivity to the different cells. This finding does not rule out a non-selective cytotoxic
effect of the extract on the cells of all types.
Table 4.3: Anticancer activity of the extracts
Sample Extract type In-house Cancer Results*f NCI Results*f
4-A aqueous Not active Not done
4-B orgamc Weak Weak, no selectivity
• The criteria to used for classifying results is defined in chapter 3, section 3.5.1 and 3.5.2
Weak -- NCI: 10gGIso between 1.) Oppm and 1.50ppm and CSIR: TGI between lSppm and 50ppm
r Test concentration IOOppm
The same extract 4-B was re-tested (at CSIR) at five serial dilutions at concentrations
between 6.25 and 100 llg/ml and the result thereof is given in the form of a graph in Fig.
4.5.
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Figure 4.5: Anticancer activity ofthe methanol-dichloromethane extract
TGI was calculated for 4-B as 50 flg/ml, but the renal cell line had selective TGI at a
concentration less than 50 flg/ml. According to the set criteria, total inhibition of the
growth of cancerous cell achieved at extract concentrations less than 50.0 flg/ml is
considered weak. Based on this result, it was decided to identify and isolate the active
compound(s) by chromatographic fractionation of the organic extract 4-B.
The hexane (4-C), dichloromethane (4-D) and water (4-E) based fractions obtained from
liquid-liquid partitioning were evaluated at five dose response for their cytotoxic activity
against the three cell lines. The result of this experiment is shown in Fig. 4.6 as a dose-
response graph.
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Figure 4.6: Graphical representation of the cytotoxic effect ofthe liquid-liquid partitioning
fractions against cancer cells.
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From the graphs it is evident that the non-polar hexane fraction 4-C does not contribute to
the anticancer activity. The highly polar fraction 4-E showed low activity that could be
attributed to the carry over of some compounds during the liquid partitioning. Only the
dichloromethane fraction 4-D gave an improved inhibition of the anticancer cells in vitro
and a TGI concentration of less than 20.0 Ilg/ml for all three cell lines. This is more than
half the concentration at which the active extract 4-B showed the total inhibition. The
dichloromethane fraction 4-D was tested at NCI in the 60 cell line panel to confirm the
observed increase in activity and it exhibited a mean log GIso of 0.71 Ilg/ml together with a
10gTGI of 1.59 Ilg/ml which according to the criteria set is considered moderate. Of
interest was the selectivity of the fraction in this cytotoxicity assay against the sixty cell
lines as it was selective for the leukaemia, NSCLC, renal and PC-3 prostate. This is
considered a significant improvement to the crude extract activity which was only
moderate with no selectivity.
Further fractionation by repeated flash silica chromatography of the active
dichloromethane fraction yielded ursolic acid (4.5) and a-amyrin (4.6). Both compounds
were tested at five dose concentrations but at slightly lower concentrations than the extract
and fractions test concentrations (Fig. 4.7). Only ursolic acid (4.5) shows activity that was
found to be well below an extrapolated TGI less than 18.5 Ilg/ml (40.5 IlM). The NCI
calculated the logarithmic GIso of 5.11 Ilg/ml obtained from the averaged sixty cell lines
screening results.
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Figure 4.7: Anticancer activity ofursolic (4.5) acid and a-amyrin (4.6)
4.4.1. Reported biological activities of ursolic acid
Ursolic acid (4.5), also known as urson, prunol, micromerol and malol, is a pentacyclic
triterpenoid that occurs naturally in a large number of vegetarian foods, medicinal herbs,
and other plants. For a long time, it was considered to be pharmacologically inactive.
However, it was found to be biologically active both topically and internally.
Pharmacological effects reported include anti-tumor, hepatoprotective, anti-inflammatory
(oral and topical), antiulcer, antimicrobial, anti-hyperlipidemic, antiviral and anti-HIV 17
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activity. Its anti-inflammatory,18 antitumor (skin cancer)19,20 and antimicrobial properties
make it useful in cosmetic applications.21
This compound is also reported as an anti-infective agent, antineoplastic agent and
phytogenic cyclooxygenase inhibitor.22 In vitro the compound exhibits anticancer activity
against the host cells with effective dose (ED5o which can be translated as same to GIso)
ranging from 3.2 to 4.6 f.lg/ml.23,24 It was also reported that ursolic acid induces apoptosis
in human melanoma (M4Beu) with EDso of20 f.lM.25
4.5. CONCLUSION
Ursolic acid (4.5) was isolated as the active constituent from P. paniculata. This compound
and its derivatives have been patented for their anticancer properties.26 The NCI published
their own screen results of ursolic acid tested against their sixty cell lines as an averaged
logarithm GIso of 5.11, TGI of 4.78 and LCso of 4.39 f.lg/ml.27 Triterpenoids play a vital
role as anticancer agents and structural modification of this class of compounds can result
in the establishment of an innovative drug for the treatment of cancer. The downside of
using triterpenoids in general is that their cytotoxicity is associated with their haemolytic
and cytostatic properties and this necessitates the synthesis of analogues of low toxicity
and improved potency.
54
Chapter 4: Bioassay-guided isolation and anticancer activities ofP. paniculata
4.6. EXPERIMENTAL
General experimental techniques are described in Chapter 3.
4.6.1. Plant material identification
A fresh herbarium plant sample was collected from Perseverance farm (GPS: 25°51' 59S;
27°29' lIE), R24 Marikana off ramp, Northwest Province, during September 1999 and
identified by Mr. E Nienaber. A voucher specimen of the collected plant was deposited at
the South African National Biodiversity Institute (SANBI) in Pretoria and the plant was
identified as Phylica paniculata Willd. (Genspec No.: 4886000) belonging to the
Rhamnaceae family.
4.6.2. Extraction and isolation of compounds
The fresh plant leaves (979.10 g) were oven dried at 45°C. The dry plants were ground to
a powder. The ground material was divided into two portions of unequal proportion. One
portion (680.50g) was subjected to sequential extraction, first with purified water enough
to cover the plant material and then the oven-dried residual plants were extracted with a
50% methanol-dichloromethane mixture covering the plant to afford the aqueous extract
(4-A, 3.41 g) and organic extract (4-B, 20.24 g) extracts, respectively. The organic extract
(4-B) exhibited a low activity whereas the water extract was inactive. Results from the 60
cell line screen at NCI confirmed the low and non-selective anticancer activity of the
extract 4-B. The remaining portion of plant material (298.60 g) was extracted with
dichloromethane to afford the extract 4-G (11.84 g, Fig. 4.4.).
Extract 4-B (3.15 g) was subjected to liquid-liquid partitioning and afforded three fractions
4-C (0.19 g, hexane extract), 4-D (0.76 g, dichloromethane extract) and 4-E (1.14 g, water
extract) of which only the dichloromethane fraction (4-D) was active with improved
anticancer activity as compared to the crude extract 4-B. Fraction 4-D was also tested at
the NCI and showed moderate activity selective for leukaemia, NSCLC (Non-Small-Cell
Lung Cancer) and PC-3 prostate cell lines. Fraction 4-D was chromatographed on silica gel
and elution with increasing polarities of dichloromethane-methanol generated 16 fractions
of quantities ranging between 0.9 mg and 84.3 mg. The last eight fractions as eluted per
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polarity range retained the anticancer activity and they were combined. The pooled (160
mg) fraction was purified on flash silica gel 60 (dichloromethane-2% methanol) to afford
fractions 4-Fl (19 mg) and 4-F2, a triterpenoid 4.5 (8.0 mg, Rf 0.18 using 1:4 ethyl
acetate-hexane). The compound was not visible under ultraviolet light (254 nm), but it was
visualised as a yellowish-pink spot after spraying the TLC plate with vanillin-sulfuric acid,
the color changed to bright purple when heated. Increasing the polarity of the eluting
solvent to dichloromethane-methanol (5%) resulted in the generation of seven fractions 4-
F3 (17 mg), 4-F4 (15 mg), 4-F5 (6 mg), 4-F6 (7 mg), 4-F7 (7 mg), 4-F8 (23 mg) and 4-F9
(4 mg).
In order to identify other compounds that are present in the extract, semi purification of the
methanol-dichloromethane extract (4-B, 11 g) by liquid-liquid partitioning was repeated.
The generated dichloromethane fraction (4-D, 3.57 g) was combined with the
dichloromethane extracts (4-G, 2.58 g) obtained by extracting the ground plant material.
Flash column chromatography of this combined material starting from chloroform and
stripping the column with methanol resulted in the recovery of eight fractions with masses
ranging between 45 mg and 1000 mg. Fraction 4-Hl was purified by flash chromatography
and afforded seven semi-pure and pure compounds (see Fig. 4.7 & 4.8 for compounds
isolated) and they were all sent for IH and I3C NMR experiments. All of these compounds
except one showed a very intense CH2 peak which makes it difficult to identify the
compounds by NMR. The compound was analyzed by GC-MS and no good match was
obtained when compared to compounds in the library.
Fraction 4-H3 was further purified by flash chromatography and afforded more of
compound 4.5 (ursolic acid) and another compound that was identified as a-amyrin (4.6,
7.3 mg).
The NCI published their own screen results of ursolic acid tested against their sixty cell
lines as an averaged logarithm GIso of 5.11 Ilg/ml.
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4.6.3. LC-MS analysis of extracts
LC-MS experiments were performed usmg Alliance waters 2690 separations module
system (HPLC) interfaced with a Micromass Quattro LC mass spectrometer. The mass
spectrometer was operated in the positive mode using electrospray interface. The samples
concentrations, 5000 ppm for the extracts and 2500 ppm for the fractions were prepared by
dissolving 5-10 mg of the sample in 2 ml of methanol-acetonitrile (1: 1) and injecting 25 J.ll.
The mass spectra was set to scan from 50 to 2000 amu, cone volatage of 80 V, Capillary
voltage of 3.0 kV, extractor at 5 V, desolvation and source block temperatures at 350 and
130 °c respectively. The variable PDA detector was scanning from 193 to 400 nm.
Table 4.3: Solvent gradient used to separate the metabolites in the extract





















[a]D +66.3 (c = 0.33) m EtOH (Merck Index28
reported [a]D +67.5 at c = 1.0 in KOH).
m/z 456, C30~803. base peak 248 [M-208t, 203 [M-
253t, 133 [M-323t, 43 [M-413t.
See Table 4.1 (CDCb/CD30D)
See Table 4.1 (CDCh/CD30D)
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[a]D +88.9 (c = 0.11) In CHCh+MeOH (Merck
Index28 reported [a]D +96.5 at c = 1.0 in CHCh)
m/z 426.72, C30HsoO with base peak 248.1769 [M-
208t, 203.18 [M-253t, 133.09 [M-323t
See Table 4.2 CCDCh)
See Table 4.2 CCDCh)
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ISOLATION AND BIOLOGICAL ACTIVITIES OF COMPOUNDS
FROM PERGULARIA DAEMIA
5.1. INTRODUCTION
Information on a plant prescribed by traditional doctors to pregnant woman to prevent pain
and birth difficulties was brought in by the late chairperson of the THC, TDr Solomon
Mahlaba. The plant is traditionally known as Lushe (Tswana) or Mothuhu (Pedi). An
infusion is prepared by boiling one tablespoon of dry ground plant powder in 1 L water for
one and a half hours. A cup of the cold extract is taken per day. No side effects were
reported for this plant except for the bitter taste of the infused tea. Evaluation of the plant
involved the preparation of suitable organic and aqueous extracts of the plant according to
pharmaceutical and traditional procedures.
These extracts were tested in vitro for cytotoxicity against three highly sensitive cancer cell
lines available at the CSIR laboratories (melanoma UACC62, renal TK10 and breast
MCF7). The organic extract (methanol-dichloromethane, 1: I, v/v) inhibited the growth of
cancer cells and warranted further purification to isolate the active principle. This chapter
is focused on the phytochemical investigation of the plant.
5.1.1. Botanical aspects of Pergularia daemia
Pergularia daemia (Forssk.) Chiovenda (Asclepiadaceae) is an herbaceous creeper with
milky latex and hairy stems that smells like fish. The plant's latex is used as fish poison. l
This plant grows up to 3 m in height and the heart-shaped leaves are pale-green and heart-
shaped with hairy petioles (50 mm) always longer than the blade. The small, creamy
flowers are borne auxiliary in drooping clusters. Flowers are bell-shaped with furry stems
and petals, followed by paired, rough, homed fruits on long stems. Seeds are covered with
long, silky floss. Flowering time is from late spring into summer.5
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Pictures courtesy of' Peoples Plants' I
Figure 5.1: Pergularia daemia
Synonyms for P. daemia. are P. extensa N.E.Br., P. edulis Thunb., Daemia extensa R.Br.,
D. angolensis Decne., D. aethiopica Decne., D. cordifolia K.Schum. ex Engl. and
Asclepias daemia Forssk. Vernacular names used are Mothuho (Pedi), Lushe (Tswana),
milkweed family (English) and bobbejaankambro (Afrikaans).
This plant speCIes is widely distributed in tropical Africa in moist areas and is often
cultivated as an ornamental. The genus Pergularia (synonym Daemia) contains toxins that
make it useful as hunting or fishing poisons in remote areas. P. daemia is widely
distributed in central Africa whereas P. tomentosa is distributed in western Africa and
some other parts of southern Africa.2
5.1.2. Ethnopharmacology
Anecdotal information of P. daemia showed that the plant was widely used by people in
rural areas for nausea, depilatory, abortion and treatment of skin diseases, amongst others.3
P. daemia is also used in India as a folk medicine for the treatment of liver disorders.4 It
was shown that an ethanol extract from the aerial parts possessed significant
hepatoprotective properties in rats after an oral dose of 200 mg/kg and no signs of acute
toxicity were observed up to a dose level of2000 mg/kg.4
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Root decoctions are taken for'venereal diseases, arthritis, muscular pain, asthma and
rheumatism. The leaves are eaten cooked as spi-nach. I-5 The dried, pulverized roots are
rubbed into stiff muscles and joint pains. In addition, cooked leaves of the plant are edible
and work as an anthelmic, causing nausea.6 Insects that fed on the plant were reported to
have been intoxicated. 7 Sathish 8 reported that P. daemia has anti-inflammatory, anti-
pyretic and analgesic activity while Wahi9 reported on the anti-diabetic activity.
The roots of P. daemia have been used for fish poisoning and the subspecies leiocarpa was
reported as having diuretic properties and was utilized with milk or water for the treatment
of syphilis or blackwater fever. A related species, P. tomentosa, is applied for depilatory,
poultice, abortive, laxative and for the treatment of some skin diseases. 10
Watt and Breyer-Brandwijk11 described the plant as a pot herb. In Ghana the leaf, which
contains 5.6 mg/lOO g vitamin C, has a peculiar mousy odour and is ingested by woman
immediately after childbirth. The plant is claimed to be an emetic, has anthelmintic
properties and works as an asthma remedy.
5.2. PREVIOUS PHYTOCHEMICAL STUDIES
Dymock reported in 1891 that P. extensa, which is a synonym of P. daemia, contains an
alkaloid daemine and a bitter glycoside. In 1962 Reichstein et al. 11 identified the
cardenolides odorigenin B (uzarigenin) (5.1), coroglaucigenin (5.2), calotropin and
corotoxigenin (5.3) from P. extensa. 12
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5.2: Coroglaucigenin R = CH20H
5.3: Corotoxigenin R = CHO
R=H
5.5: Lupeol acetate R = COCH3 5.6: a-Amyrin acetate
Raman and Barua reported the presence of the triterpenoids lupeol (5.4), lupeol acetate
(5.5), a-amyrin acetate (5.6) and ~-sitosterol (5.7) in the leaves of P. extensa. 13,14 The roots
contained less cardenolides and triterpenoids than the aerial parts. 15
A literature search on the closely related speCIes P. tomentosa showed that steroidal
compounds, namely ~-sitosterol (5.7), ghalakinoside (5.10) and calactine (5.9), as well as a
nitrogenous base, choline were isolated. The cardenolide glycoside uzarigenin was shown
to be present in the extracts of P. tomentosa along with the sugar moiety, glucose and
digitoxose. Recently ~-sitosterol glucoside (5.8) was added to the number of compounds
isolated from the aerial parts ofP. tomentosa.1 6
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R = glucosyl I~
LOH OH J
Ghalakinoside (5.10) showed a strong inhibitory activity in vitro against cells derived from
the human carcinoma of the pharynx (EDs = 2.9x 10-
2 Ilg/ml). 10,17 An EDso of 4 Ilg/m1 for
pure compounds is considered positive for antitumor screening. The extracts of the plant
proved to be toxic to mice by intraperitoneal administration in 0.1 ml amounts. 18 From the
roots of P. tomentosa, compounds 5.9 and 5.10 and other cardenolides caused apoptotic
cell death of Kaposi' s sarcoma cells as can be expected from their cytotoxic activity
against a large range of cancer cell lines. 19
o
5.9: Calactine H CHO ~-OH
5.10: Ghalakinoside OH CH20H a-OH
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Five phenanthrolizidine alkaloids pergularinine (5.11), tylophorinidine (5.12), tylophorine
(5.13), deoxypergularinine (5.14)20 and tylophorinicine (5.15) were isolated from the roots
of the related species Pergularia pallida. Tylophorinicine was also isolated from
Tylophora asthmatica. 21 Pergularinine and tylophorinidine exhibited significant antitumour
activity in vitro by inhibiting the leukaemia leukocyte enzyme dihydrofolate reductase (EC
2.1.1.45), 22 which is a key target in cancer chemotherapy and was purified from
Lactobacillus leichmannii. 23
RI R 2 R3
R
2
5.11: Pergularinine OCH3OH H
H3CO
5.12: Tylophorinidine H OH OH
5.13: Tylophorine H OCH3 OCH3
5.14: Deoxypergularinine H H OCH3
5.15: Tylophorinicine OH OCH3 OCH3
OCH3
Two pregnane ester glycosides, pallidine (5.16) and pallinidine (5.17), were isolated from
the twigs of P. pallida and their structures contain one glucosyl or two glucosyl units for
pallidine and pallidinine, respectively.24
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5.17: Pallidinine R =
A pregnane genin was isolated from the chloroform extract of the dried twigs of P. pallida
and earlier from Sarcostemma brevistigma and was identified as sarcogenin






The present study followed after a chemical investigation of the dried twigs of P. pallida
revealed the presence of a-amyrin (5.19), p-amyrin (5.20), sitosterol (5.7), drevogenin B
and cissogenin.26
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This study was aimed at isolating the compounds that were responsible for the cytotoxic
effect of the plant extract on the three cancer cell lines that are used in the study. However,
compounds without activity were also isolated to gain information on the secondary
metabolites present in this plant. Most of the compounds reported in the literature were
from related genera and only a few have been identified by analytical techniques.
5.3. ISOLATION AND STRUCTURAL ELUCIDATION OF ACTIVE
COMPOUNDS
The methanol-dichloromethane extract of the oven-dried and ground plant of Pergularia
daemia exhibited cytotoxic effects at a concentration of 100 Ilg/ml in the three cancer cell
lines (breast, melanoma and renal). The aqueous extract did not show a significant
inhibition of the growth of these cancerous cells at the same concentration, hence no
further work was done on this extract. The fractionation procedure is outlined in Fig. 5.2
and it involved the primary purification of the organic methanol-dichloromethane extract
to afford the partitioned hexane, dichloromethane and water fractions. Only the
dichloromethane fraction showed a significant increase in anticancer activity.
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Figure 5.2: Schematic diagram of the fractionation and isolation of compounds from
Pergularia daemia.
Column chromatography of the final dichloromethane fraction was done on silica gel by
means of vacuum liquid chromatography (VLC) using various solvent systems. Seven
fractions were generated and post purifications of three of these fractions as shown in Fig.
5.2 afforded five pure compounds. Although the water fraction obtained by liquid
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partitioning did not show activity in the anticancer screen, fractionation of this resulted in
the isolation of a carbohydrate that was identified as sucrose.







TLC indicated that this compound is highly polar. In the 13C NMR spectrum twelve
signals were observed in the region between be 61 and be 104. These chemical shifts are
characteristic of carbon atoms attached to highly electronegative atoms such as oxygen,
and indicate that the compound may be a carbohydrate.
The one anomeric carbon signal at be 92.4 is characteristic of a-orientation of the hydroxyl
group attached to position C-I whereas the signal at be 104.7 is corresponding to a
quaternary carbon. The most common disaccharide with a quaternary acetal carbon is
sucrose. NMR data of compound 5.21 were in close agreement with published data for
sucrose (Table 5.1).
Mass spectral data that were determined by ESIMS- indicate a [Mr 341.2 which is in
support of the molecular formula Cl2H22011 - [H+]. The specific optical rotation of the
compound at 20 QC was determined as + 66.7 (c = 10.5 mg/lO ml) which is similar to the
reported value for sucrose + 66.0 ± I (c = 1.2 g/1 00 ml in H20) obtained from literature.27
the Merck Index.28
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Table 5.1: NMR spectroscopic data for sucrose (5.21)
Sucrose
Isolated compound' Literature29#
Carbon Oc OH (J in Hz) Oc OH
1 92.4 5.12 93.20 5.41
2 72.3 3.13 72.14 3.56
3 73.5 3.61 73.68 3.76
4 70.5 3.07 70.31 3.86
5 73.4 3.42 73.44 3.47
6 61.1 3.58 61.24 3.81
I' 62.7 3.58,3.35 (2H) 62.46 3.67
2' 104.7 104.71
3' 77.7 3.83 77.51 4.21
4' 75.0 3.72 75.09 4.05
5' 83.2 3.52 82.42 3.89
6' 62.7 3.49 63.44 3.83
* Data obtained in DMSO, DC at 100.5 MHz and 'H at 400 MHz
# Data obtained in 0,0, DC at 100 MHz and I H at 400 MHz
Results obtained from SABS also confirmed the structure of the compound by using he
analytical method published in the European Pharmacopoeia.3o







~-Sitosterol was isolated from the dichloromethane fraction obtained from the liquid-
liquid partitioning of the methanol-dichloromethane (1 :1) extract of the plant.
This compound was compared to an authentic sample of ~-sitosterol that was bought from
Sigma-Aldrich. Thin-layer chromatography gave the same Rf for both samples and the
same pink color after spraying the TLC plate with vanillin and baking in the oven. The
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assignment was corroborated by NMR experiments, which showed that the commercial
sample of p-sitosterol gave identical l3C and IH spectra with CDCb as solvent. Literature
studies also revealed that the l3C signal that is supposed to be seen for C-2 overlaps with
the one in C-7 or C-8 and the peak signal for C-4 overlaps with the signal of the peak in C-
13. 31 The IH NMR and l3C NMR assignments were also correlated with previously
published spectral data.32 This evidence substantiated that the structure is p-sitosterol.




C be DEPT bH(Jin Hz) be bH(Jin Hz)
CH2 1.05 (m)
37.2 1.89 37.1 1.83 (m)
CH2 1.82 (m)
2 31.6 1.56 31.5 1.48 (m)
3 71.8 CH 3.49(m) 71.7 3.48 (m)
4 42.4 CH 2.28 42.2 2.28 (m)
5 140.7 C 140.8
6 121.7 CH 5.32(d,5.0) 121.7 5.32(d,5)
7 31.8 CH2 1.53 31.7 1.53 (m)
8 31.7 CH 1.93 31.7 1.90 (m)
9 50.1 CH 0.98 50.0 0.87 (m)
10 36.5 C 36.3
11 21.1 CH2 1.51 20.9 1.43 (m)
12 39.8 CH2 2.03 39.6 1.13 (m) 1.99 (m)
13 42.3 C 42.7
14 56.8 CH 0.99 56.7 0.94 (m)
15 24.3 CH2 1.61 24.1 1.13 (m) 1.61 (m)
16 28.2 CH2 1.85 28.1 1.35 (m) 1.86 (m)
17 56.1 CH 1.12 55.9 1.06 (m)
18 11.9 CH 3 0.64 (s) 11.7 0.65 (s)
19 19.4 CH3 0.93 (s) 16.7 1.00 (s)
20 36.1 CH 1.37 36.0 1.32 (m)
21 19.4 CH3 0.93 (d, 7.0) 19.2 0.92 (d, 7.0)
22 34.0 CH2 1.35 33.8 0.99 (m) 1.26 (m)
23 26.1 CH2 1.20 25.9 1.12 (m)
24 45.9 CH 0.96 45.7 0.95 (m)
25 29.2 CH 1.70 29.0 1.62 (m)
26 19.8 CH3 0.83 (d, 7.0) 18.9 0.88 (d, 7.0)
27 19.0 CH3 0.81 (d, 7.0) 18.6 0.77 (d, 7.0)
28 23.1 CH2 1.27 22.9 1.20 (m)
29 12.0 CH3 0.84 (t, 7.0) 11.8 0.82 (t, 7.0)
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A molecular mass [Mt of m/z 414 in the mass spectrum is In agreement with the
molecular formula of C29HsoO. The molecular formula was in agreement with the
successive loss of 85 units to m/z 329. The molecular ion peak underwent the loss of a
water molecule to m/z 396 followed by a loss of m/z 15 attributed to loss of CH3 to m/z
381. The side chain (C20 - C29) was cleaved and left an atomic mass unit of m/z 289.











P-Sitosterol p-o-glucoside was isolated from the dichloromethane fraction (Fig. 5.4) as a
white amorphous substance. This compound is polar and could only be dissolved in
methanol with heating or by a combination of solvents for example methanol, acetone and
chloroform. Thus, NMR data were obtained by dissolving the sample in DMSO. The
obtained proton and carbon spectral data were interpreted and the structure of a steroidal
glycoside was evident.
The IH NMR spectra and 13C NMR spectra were almost identical to those of P-sitosterol,
except for the presence of the signals associated with a glycoside moiety. The 13C NMR
spectrum of the isolated compound showed 35 carbons. The chemical shifts of the sugar
attached to the sitosteryl in Table 5.4 were compared to published data and was identified
as p-o-glucosyl. The IH NMR spectral data showed three distinct singlet peaks of the
methyl substituents at bH 0.64 (H-29), 0.81 (H-I8) and 0.94 (H-19) as compared to those of
73
Chapter 5: Phytochemistry ofPergularia daemia
the published sitosteryl at bH 0.66, 0.89 and 0.93, respectively. Olefinic carbons were
observed at be 121.1 and 140.4, which correspond to the quaternary C-5 and the methine
C-6, respectively. The l3C NMR spectral assignments for the ~-sitosterol fragment
compared to previously published l3C NMR data for the glycoside is given in Table 5.3.
Table 5.3: l3C NMR and IH NMR chemical shifts of the isolated ~-sitosterol glucoside




C Bc BH (l in Hz) Bc BH
1 36.7 0.95 37.2 1.69; 0.94
2 29.2 2.12 29.4 2.12; 1.74
3 76.9 3.96 78.4 3.95
4 38.2 2.44 38.9 2.73; 2.46
5 140.4 140.8
6 12\.1 5.34 (d, 5.0) 121.9 5.35
7 31.3 1.88 3 \.9 1.87; 1.54
8 31.3 1.30 31.8 \.34
9 49.5 0.88 50.1 0.90
10 36.1 36.5
11 20.5 1.40 21.1 1.40
12 39.7 1.14 39.7 1.98; 1.12
13 41.8 42.2
14 56.1 0.91 56.7 0.91
15 23.7 1.07 24.2 1.54; 1.00
16 27.7 \.21 28.2 \.85; 1.23
17 55.3 1.09 56.0 \.09
18 11.6 0.66 (s) 11.9 0.64
19 19.0 0.95 (s) 19.5 0.94
20 35.4 1.35 36.1 1.38
21 18.5 0.86 (d, 6.4) 18.8 0.84
22 33.3 1.08 33.9 1.38; 1.10
23 25.4 1.24 26.0 1.25
24 45.1 0.94 45.8 0.94
25 28.6 \.67 29.1 1.67
26 19.6 0.86 (d, 6.4) 19.8 0.87
27 18.8 0.86 (d, 6.4) 19.0 0.87
28 22.5 1.22 23.0 1.20
29 11.7 0.87 (t, 6.4) 12.0 0.85
The compound has been assigned as ~-sitosterol D-glucoside. The aglycone was positively
identified as ~-sitosterol and attached to C-3 of the aglycone is a beta D-glucosyl moiety.
This data were confirmed by l3C data of published sitosterol glucoside.33,34 The spectral
assignments for the aglycone and the glucoside moiety are given in Table 5.3 and 5.4
respectively and are compared to previously published data.
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Table 5.4: 13C NMR and IH NMR chemical shifts of the isolated ~-sitosterol glucoside




C be bH (J in Hz) be OH
I' 100.7 5.04 (d, 7.7) 102.6 5.05
2' 73.4 4.04, (t, 8.2) 75.4 4.06
3' 76.6 4.31, m 78.1 4.28
4' 70.0 4.31, m 71.7 4.28
5' 76.7 4.01 (t, 4.9) 78.6 3.97
6' 61.0 4.40 (d, 11.7) 62.8 4.40
4.55 (d, 11.7) 4.57
In the mass spectrum, a molecular ion peak of m/z 576 was obtained for as ~-sitosterol ~-D­
glucoside which is consistent with a molecular formula of C35H6006. The loss of the
glucose moiety (m/z 180) resulted in the formation of the fragment with m/z 396, followed
by the loss of a CH3 (15) resulting in a fragment peak at m/z 381.





This compound was isolated from subsequent dichloromethane fraction purification by
silica column chromatography. It was obtained as white amorphous solids at room
temperature that was soluble in chloroform. Based on NMR data (Table 5.5), the structure
of the compound was assigned as a-amyrin. The structural elucidation of this compound
was described in section 4.3.2.
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Table 5.5: I3C and 'H NMR data ofa-amyrin (5.19) observed at 100.5 MHz and 399.9
MHz respectively, in CDCi).
a-amyrin
LiteratureJ5Observed, 5.19
C be DEPT bH (J in Hz) Be
1 38.9 CH2 38.7
2 23.4 CH2 1.64 (m) 27.2
3 79.2 CH 4.53 (m) 78.3
4 37.1 C 38.7
5 55.4 CH 55.2
6 18.5 CH2 18.3
7 33.1 CH l 32.9
8 40.2 C 40.0
9 47.9 CH 47.7
10 37.1 C 36.9
11 23.5 CH l 1.86 (m) 23.3
12 124.6 CH 5.09 (t, 3.6) 124.3
13 139.7 C 139.3
14 42.2 C 42.0
15 28.3 CH2 28.7
16 26.8 CH 2 1.03 26.6
17 33.9 C 33.7
18 59.2 CH 1.21 58.9
19 39.8 CH 39.6
20 39.8 CH 39.6
21 31.4 CH2 31.2
22 41.7 CH2 41.5
23 28.9 CH3 0.79(s) 28.1
24 17.0 CH3 0.83 (s) 15.6
25 15.8 CH3 0.94 (s) 15.6
26 17.0 CH3 0.87 (s) 16.8
27 23.4 CH3 1.02 (s) 23.3
28 28.3 CH3 0.83 (s) 28.1
29 17.6 CH3 0.75 (d, 5.5) 17.4
30 21.5 CH3 0.97 (d, 5.5) 21.3
Confirmation for the structure of this compound was obtained by comparison of the NMR
data with published data35 in a review article oftriterpenoids.36
5.3.5. Characterization of a-amyrin acetate (5.6)
Compound 5.6 exhibited six tertiary methyl singlet signals at OH 0.80, 0.83, 0.94, 0.97, 1.02
and 0.83 and two methyl doublet signals at OH 0.75 and 0.87 in the IH NMR spectra (Table
5.5). It further showed an olefinic proton resonating at OH 5.08 (lH, d, J=3.5 Hz, H-12) and
a singlet at OH 2.00 (3H, s, H-32), which is characteristic of an acetate group. A one-proton
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doublet at OH 1.27 characteristic of H-18 and a methine proton, gemina1 to an ester, that
resonated at OH 4.46 was also identified.
The carbon-13 spectral data (Table 5.6) of compound 5.6 were compared to the
spectroscopic data of a-amyrin (5.19) (Table 5.5) and it was observed that the only
difference between the two compounds was the number of carbon signals. The peak at Oc
81.1 was assigned to the acetate-containing carbon at position 3 with the carbonyl of the
acetate resonating at Oc 171.1 and its terminal methyl at Oc 21.5. The presence of the
acetate at C-3 was observed by the chemical shift of C-2 that resonated at Oc 23.7 as
compared to about Oc 27.2 when an OH is attached to C-3. Two single protonated carbons
had distinct signals at Oc 55.4 and Oc 59.2 for the carbons C-5 and C-18, respectively. The







Comparison of the chemical shifts of C-12 and C-13 gives evidence to the position and
orientation of the methyl C-29 and C-30. This is provided by the resonance of the 19-P
methyl at Oc 39.7 in the equatorial position, which is in close proximity to the double bond.
In oleanolic compounds a methylene group is at position 19, but if a P-OH is attached to C-
19 of oleanolic derivatives, the double bond shifts will appear at the same chemical shift as
those of ursolic derivatives. Further confirmation was obtained from the shift of C-18 that
is shielded by approximately Oc 11.5 in oleanolic derivatives as compared to ursolic
derivatives and to the 20P axial methyl group at Oc 39.8.
77
Chapter 5: Phytochemistry ofPergularia daemia
The mass spectral data obtained from the GC/MS matched that of urs-12-en-3-o1 acetate
which gave a molecular ion [Mt of m/z 468, which is in agreement with the assigned
molecular formula ofC32Hs202. The base line peak was observed at rn/z 218 [C 1sH220t.




C be DEPT bH (J in Hz) be
1 38.6 CH2 1.59 38.7
2 23.7 CH2 1.59-1.64 (m) 27.2
3 81.1 CH 4.46 (m) 78.3
4 37.9 C 38.7
5 55.4 CH 0.80 55.2
6 18.4 CH2 0.75-0.76 18.3
7 33.0 CH2 0.83 32.9
8 40.2 C 40.0
9 47.8 CH 1.49 47.7
10 36.9 C 36.9
11 23.5 CH2 1.86 (m) 23.3
12 124.5 CH 5.08(t, 3.6) 124.3
13 139.8 C 139.3
14 42.2 C 42.0
15 28.2 CH2 0.76 28.7
16 26.7 CH2 1.07 26.6
17 33.9 C 33.7
18 59.2 CH 1.27 58.9
19 39.7 CH 39.6
20 39.8 CH 39.6
21 31.4 CH2 31.2
22 41.7 CH2 41.5
23 28.9 CH3 0.80 28.1
24 16.9 CH3 0.83 15.6
25 15.9 CH3 0.94 15.6
26 17.0 CH3 0.97 (s) 16.8
27 23.4 CH3 1.02 (s) 23.3
28 28.2 CH3 0.83 (s) 28.1
29 17.6 CH3 0.75 17.4
30 21.4 CH} 0.87 (s) 21.3
31 171.1 C
32 21.5 CH3 2.00 (s)
13C observed at 100 MHz and I H observed at 400 MHz
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5.3.6. Characterization of coroglaucigenin (5.2).
HO
5.2: Coroglaucigenin
This compound was isolated as a white amorphous substance that showed up a violet color
under short wave UV light (254 nm) on a TLC plate. The molecular ion peak was obtained
by ESIMS operating in the negative mode resulting in m/z 434.9 that corresponds to [M-
H+HC02Hr which is [M+45r. The calculated molecular weight was in accordance with
the molecular formula C23H340 S.
Examination of the IH NMR spectrum confirmed its steroidal nature by a senes of
multiplets from bH 0.7 to 2.4 and the presence of the characteristic a,~-unsatuated lactone
of the cardenolide. The latter group was represented by a broadened singlet at bH 5.79 (lH,
22-H) and a pair of non-equivalent methylene protons at bH 4.94 and 4.76 Only one
steroidal methyl was observed (bH 0.83, be 15.6) and it was clear that a hydroxyl group is
present on C-19 (bH 3.75 & 3.64 with J = 12 Hz, be 59.0).
In the l3C NMR spectrum of this compound there were 23 carbon signals. This number of
carbons and the spectra pattern was viewed as typical of the steroids. The structure of this
compound was further authenticated by comparison of the I3C NMR data of 5.2 with that
of coroglaucigenin which was previously isolated from Pergularia extensa.
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Table 5.7: 13C NMR and I H NMR chemical shifts of the cardenolide 5.2 in CDCh and a
few drops ofCD30D (oc 125 MHz and OH 500 MHz).
Coroglaucigenin
Observed, 5.2 Literature 10.37
C be bH be bH
I 32.4 33.0
2 31.7 32.7














17 50.7 2.70 (dd, 10,5) 51.6 2.78 dd
18 15.6 0.83 16.3 0.92
19 59.0 3.75 (d, 12.0) 59.2 3.85 dd
3.64 (d, 12.0)
20 175.7 \76.2
21 73.7 4.94 (dd, 17.8, 1.4) 73.4 4.80
4.76 (dd, 17.8, 1.7)
22 117.0 5.79(s) 1\7.6 5.88
23 175.3 174.6
5.4. BIOLOGICAL ACTIVITY
The noted anecdotal information of the plant when it was delivered to the CSIR by a
representative of the Traditional Healers Committee had no evidence of its efficacy as an
anticancer candidate. A methanol-dichloromethane extract of the whole plant of P. daemia
was prepared according to pharmaceutical preparations and the aqueous extract was
prepared as done by traditional doctors.
The prepared extracts were evaluated for cytotoxic activity at a single dose concentration
of 100 flg/ml against a panel of three cell lines (melanoma, renal and breast cell lines). The
aqueous extract exhibited a TGI of greater than 100 flg/ml and the organic methanol-
dichloromethane extract showed moderate activity. The methanol-dichloromethane extract
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was then retested at five dilution concentrations ranging between 6.25 and 100 Ilg/ml and a
TGI of 25 Ilg/ml obtained (results shown in Fig. 5.4) The extract has moderate activity
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Figure 5.3: Dose-response curve of the anticancer activity of the organic extract.
The same extract was sent to the NCI laboratories for evaluation in the 60 cell line panel.
The extract has a mean log GIso of 1.11 J.1g/ml. The inhibition activity was specific for the
NSCLC, renal and prostate DU 145 cancer cell lines.
The extract was then partitioned to obtain the hexane, dichloromethane and water fractions.
Screening of these fractions for anticancer activity at the CSIR showed that only the
dichloromethane fraction had significant improved activity (see Fig. 5.4). The slight
activity of the water fraction might be a false positive coming from the carry over from the
dichloromethane-water partitioning.
Repeated column chromatography of the dichloromethane fraction resulted in the isolation
of five compounds, two steroids B-sitosterol (5.7) and B-sitosterol glucoside (5.8), two
triterpenoids of the ursane type a-amyrin (5.19) and a-amyrin acetate (5.6) and a
cardenolide coroglaucigenin (5.2). Sucrose (5.21) was isolated from the water fraction
obtained from liquid partitioning. In the CSIR laboratories, only the cardenolide 5.2
showed potent activity and a noteworthy activity was observed for a-amyrin, 5.19 (Fig.
5.5).
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Figure 5.4: Anticancer activity of the hexane, dichloromethane and water fractions
obtained from liquid-liquid partitioning ofthe methanol-dichloromethane extract.
_Ceillinel(Renal)







20 ........- Cell hne 2 (Melanoma)
















:~ I :::, II'---------II=~::::::~~:::~)
6_25E+OO 1.2SC"OI 2.SOE"O' SOOE..o, l00E"02
Er:trolct Concentration (JIgfml)
-a- Cell IlfJe , (Renal} I
















6.25E+OO 1.25E+Ol 2,50E"Ol 500E ..01 1.00E"'02
Extract concentratIon (lJg/ml)
Figure 5.5: Dose-responds curves of the isolated compounds.
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The amyrin-type compounds are not active except for the mild activity observed for a-
amyrin. The observed activity can be attributed to the presence of the free hydroxyl group
in position C-3, because replacement of this functionality with the acetate resulted in the
total loss of activity. Coroglaucigenin exhibited the highest cytotoxic activity against the
host cancer cell lines as compared to the activity of the crude dichloromethane fraction. It
can be concluded that this is the active compound in the extract.
5.5. CONCLUSION
Six compounds, sucrose (5.4), p-sitosterol (5.7), p-sitosterol glucoside (5.8), a-arnynn
(5.19), a-amyrin acetate (5.6) and coroglaucigenin (5.2) have been isolated from P.
daemia. Compounds 5.7 and 5.19 have been isolated from this plant previously,30
whereas 5.2'4,15 and 5.6 16,17 were isolated from the related species P. extensa and 5.8 from
P. tomentosa. 19 The cytotoxic activity observed for the methanol-dichloromethane extract
on the cancer cell lines can be attributed to the cardenolide coroglaucigenin (5.2) isolated
from the organic extract. This is the first report on the cytotoxicity of coroglaucigenin.
5.6. EXPERIMENTAL
General experimental techniques are described in Chapter 3.
5.6.1. Plant material
The aerial parts of the plant were collected in Kwazulu-Natal near Ngwazuma village and
the Pongola river during March. The plant was identified by SANBI in Pretoria and a
voucher specimen has been deposited in the herbarium. The plant was identified as
Pergularia daemia (Forssk.) Chiov. Var. daemia, Genspec Number 6917000.
5.6.2. Extraction and isolation
Fresh and uncrushed aerial parts (5.698 kg) of P. daemia var. daemia were stored in a cold
room overnight before processing. Subsequently it was dried in an oven at 45 QC for three
days. The dried plants (1.264 kg) were ground to a fine particle texture (1.022 kg) suitable
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for tea bagging. This crushed material was extracted twice with methanol-dichloromethane
(1: 1, v/v). The solvent was filtered and evaporated to dryness under reduced pressure to
produce 94.27 g of greenish extract and the residual plants were discarded. The aqueous
extract was produced from ground material (0.142 kg) by boiling in water for one and half
hour. The filtrate was freeze-dried to yield 23.68 g of dry brownish powder and the
residual plant material was discarded. Evaluation of the cytotoxicity of the melanoma,
renal, and breast cancer cell lines showed that only the methanol-dichloromethane extract
was effective in inhibiting the growth of this cancer cell lines with a TGI of less than 25
~g/ml.
Primary fractionation of the methanol-dichloromethane extract involved liquid-liquid
partitioning of the extract to yield hexane, dichloromethane and water fractions. The
methanol-dichloromethane extract (88.58 g) was dissolved in 2 L of 90% aqueous
methanol which was then extracted three times with 1 L of hexane. The combined hexane
extracts were dried in vacuo to give 30.55 g extract. The methanol-water fraction was
concentrated to yield a water aliquot which was enriched with more water to 2 L. This
fraction was extracted with dichloromethane (3 x 1 L). The combined dichloromethane
fractions were evaporated in vacuum and yielded a brownish dry extract (12.84 g). The
residual water was freeze dried and amounted to a brownish powder weighing (18.11 g).
Chromatography of the water fraction (600 mg) on flash silica gel resulted in the isolation
of a carbohydrate (5.21, 72.8 mg). The crystalline sugar was analyzed by SABS in Pretoria
and confirmed to be sucrose.
The dichloromethane extract (11.78 g) was fractionated by VLC. The column was washed
consecutively with 2 L each of hexane, hexane-chloroform (1: 1 v/v), chloroform,
chloroform-acetone (1: 1 v/v), acetone and methanol. The collected fractions were pooled
based on similarities as viewed on the TLC plate as follows;
2.93 g of fraction F-5.4 was column chromatographed (CC) on flash silica gel, eluting the
column with diethyl ether-hexane of increasing polarity. Ten fractions were recovered and
out of this one fraction was a pure compound. The compound was obtained as white
amorphous solids. The compound was fully characterized by NMR data and in comparison
with published data and it was assigned as p-acetate amyrin 5.6,53.1 mg.
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Table 5.8: Fractions obtained from Vacuum Liquid Chromatography








Further attempts to fractionate 1.19 g of fraction F-5.5 was done on flash CC eluting with
5% acetone in hexane. Five fractions were collected F-5.5A, 949.3 mg which contains
most of the pink major compound and a few fluorescent compounds; F-5.5B which
contained a dark spot below that of the pink major compound, 105.1 mg; F-5.5C, 210.1
mg; F-5.5D, 76.5 mg; F-5.5E; 13.5 mg. Purification of fraction F-5.5A by CC afforded the
isolation of a triterpenoid that was characterized as a-amyrin (5.19, 21.3 mg, Rr of 0.25 in
1:9 ethyl acetate-hexane). Fractionation of F-5.5B afforded a mixture of the compound 5.19
and another compound. Silica CC of fraction F-5.5C afforded eight sub-fractions when
eluting the column with 5% ethyl acetate-hexane. One fraction yielded 12.5 mg of ~­
sitosterol 5.7 which was isolated as a white amorphous solid.
Purification of fraction F-5.7, 0.18 g on flash silica gel column chromatography (2%
MeOH/CHC13 increasing to 10%) was done and collecting fractions of 10 ml volume. The
fractions were pooled together based on TLC profile and afforded the isolation of a
compound characterized as ~-sitosterol glucoside 5.8, 30.1 mg that was obtained as
greenish amorphous solids (Rr = 0.31 in 1:9 methanol-chloroform). The solids were then
washed with acetone to remove coloured impurities. Six semi-pure fractions were collected
along with this compound and their masses ranged from 3 to 76 mg. One of these fractions
that showed moderate anticancer activity (TGI S 10 jlg/ml) was further purified on CC
































m/z [M-1Hr + 2Na+ at 434.9, C23H340 S
See Table 5.7 (CDC!))




~-Acetate, amyrin or a-Amyrin acetate
53.1 mg (0.45%)
White amorphous solid
[a]~O +76.37 (c = 0.12, CHC!)) [Lit. [a]~O +76.35 (c =
0.552, CHC!)), Merck index28]
m/z 468, C32Hs202
See Table 5.6 (CDC!))
See Table 5.6 (CDC!)
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[a)~O -38.9 (c = 0.11, CHC13) [Lit. [a):; -37 (c = 2,
CHC!)), Merck index28]
m/z 414, C29HsoO
See Table 5.2 (CDC!))
See Table 5.2 (CDC!))







[a]:; -38.9 (c = 0.11, CHCh+MeOH) [Lit. [a];\ -37
(c = 2, CHC!)), Merck index28]
m/z 576, C3sH6006
See Table 5.3 & 5.4 (DMSO)







[a]~O +96.7 (c = 0.11 in CHCh) [Lit. [a)D17 + 91.6 (c
= 1.3 in benzene). Merck index28]
m/z 468, C32Hso02
See Table 5.5 (CDC!))
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2-(3,4-Dihydroxy-2,5-bis-hydroxymethyl-tetrahydro-
furan-2-yloxy)-6-hydroxymethyl-tetrahydro-pyran-





[a]~o +66.7 (c = 0.11, MeOH), [Lit +66.1 ± 1 (c = 1.3
in H20)]
m/z 341.2, C12H22011
See Table 5.1 (DMSO)
See Table 5.1 (DMSO)
88
Chapter 5: Phytochemistry ofPergularia daemia
5.8. REFERENCES
1. Van Wyk, RE. and Gericke, N., 2000. Peoples plants, Briza Publications, Pretoria,
pp. 124, 130-133, 162 and 206.
2. Neuwinger, H.D., 1996. African ethnobotany pOIsons and drugs, Chemistry,
pharmacology, toxicology. Trans. from the Ger. by A. Porter & the author. Chapman
& Hall, London. 243-248.
3. Kokwaro, J.O., 1976. Medicinal plants of East Africa, Kenya Literature Bureau,
Nairobi.
4. Sureshkumar, S.V. and Mishra, S.H., 2006. J Ethnopharmacol., 107, 164-168.
5. Van Rooyen, N., Bezuidenhout, H. and de Kock, E., 2001. Flowering plants of the
Kalahari dunes, 150.
6. Van Koenen, E., 2001. Medicinal, poisonous and edible plants in Namibia, pp. 102,
156.
7. Mahran, G.H., Hifny, S.A. and Khary, N.H., 1965. J Pharm. Scie. UA.R, 8, 101 -25.
8. Satish, C.J., Sharma, R.A., Jain, R., Mascalo, N., Capasso, F., Vijayvergia, R. and
Mittal, C., 1998. Phytotherapy Res., 12,378-380.
9. Wahi, A K., Ravi, J., Hemalatha, S. and Singh, P.N., 2002. J Nat. Rem., 2, 80-83.
10. AI-Said, M.S., Hifnawy, M.S., McPhail, AT. and McPhail, D.R., 1988.
Phytochemistry, 27, 3245-3250.
11. Reichstein, T., Mittal, O.P. and Tamm, Ch., 1962. Helv. Chim. Acta, 45, 907-924.
12. Browser, L.P., Edmunds, M. and Moffitt, C.M., 1975. J Entomol., Ser A., 2, p. 183-
196.
13. Raman, S. and Barua, AK., 1958. JAm. Pharm. Ass., 47,559-560.
14. Talapatra, B., Basak, A., Goswami, S. and Talapatra, S.K., 1981. Ind. J Chem.
20 B, 249-250., and also Chem. Abstr. 95, 12640.
15. Seshadri, TR. and Videeswaran, S., 1971. Chem. Curr. Sci. 40,594-595.
16. Gohar, AH., EI-Olemy, M.M., Abdel-Sattar, E., El-Said, M. and Niwa, M., 2000.
Nat. Prod. Sci., 6, 142-146.
17. AI-Said, M.S., Hifnawy, M.S. and Abu-Jayyab, A., 1989. J Ethnopharmacol., 27,
235-240.
89
Chapter 5: Phytochemistly ofPergularia daemia
18. Mahran, a.H., Hifny, S.A and Khary, N.H., 1965. J Pharm. Scie. UA.R, 8, 101-
125.
19. Hamed, A.I., Plaza, A, Balestrieri, M.L., Mahalel, U.A., Springuel, LV., Oleszek,
W., Pizza, C. and Piacente, S., 2006. J Nat. Prod., 69, 1319-1322.
20. Mulchandani, N.B. and Venkatachalam, S.R., 1976. Phytochemistry, 15, 1561-1563.
21. Mulchandani, N.B. and Venkatachalam, S.R., 1984. Phytochemistry, 23, p.1206.
22. Rao, K.N., Bhattacharya R K and Venkatachalam S R, 1998. Cancer Left, 128, 183-
188.
23. Rao, N.K. and Venkatachalam, S.R, 2000. Toxicology in vitro, 14,53-59.
24. Khare, N.K., Khare, M.P. and Khare, A, 1984. Phytochemistry, 23, 2931-2935.
25. Khare, N.K., Kumar, R., Khare, M.P. and Khare, A, 1986. Phytochemistry, 25, 491-
493.
26. Khare, N.K., 1984. Dissertation, Lucknow University, Lucknow.
27. Singh, A.P., Singh, A.K., Begum, AS., Sahai, M., 2003, Phytochemistry, 63, 485 -
490.
28. Budavari, S., O'Neil, M.J., Smith, A and Heckelman, P.E., 1989. An encyclopedia
of chemicals, drugs and biologicals. The Merck Index, 11 th edition. Merck &Co., Inc.
29. Download from Spectral Data of Organic Compounds (SDBS) database;
http://www.aist.go.jp/RIODB/SDBS. accessed 17 October 2006.
30. European Pharmacopoeia, 4th edition, 2002, Analysis of carbohydrates, 1445.
31. Stothers, J.B., 1972. Carbon 13 NMR Spectroscopy, Academic press, New York,
439-447.
32. Nes, W.O., Norton, RA and Benson, M., 1992. Phytochemistry, 31, 805-811.
33. Ali, M.S., Saleem, M., Ahmad, W., Parvez, M. and Yamdagni, R, 2002.
Phytochemistry, 59, 889-895.
34. Kadowaki, E., Yosuhiro, Y., Baba, N. and Nakajima, S., 2003. Scientific reports of
the Faculty of Agriculture, Okayama University, 92, 1-4.
35. Seo, S., Tomita, Y. and Tori, K., 1981. JAm. Chem. Soc. 103,2075-2080.
36. Mahato, S.B. and Kundu, AP., 1994. Phytochemistry, 37,1517-1575.





INVESTIGATIONS OF MONSONIA ANGUSTIFOLIA
6.1. INTRODUCTION
A traditional herb for the treatment of erectile dysfunction and for the enhancement of
libido was brought to the CSIR by a traditional healer under the umbrella of the Traditional
Healers Committee (THe) committee. The committee signed a material transfer agreement
for scientific evaluation of their traditionally-used medicine. The traditional healers
prescribe an herbal tea made from the plant to their patients for the treatment of erectile
dysfunction problems. It was also observed by the traditional healers that the plant
enhanced low sexual drive (libido) for both male and female patients. Upon using the herb
in the form of tea, the patients reported improvement in both sexual dysfunction and libido.
A tea is prepared by taking a handful of the plant material and boiling in a liter of water for
thirty minutes.
Male patients who were diagnosed by traditional doctors to have an erectile dysfunction
problem took an oral dose of the traditional preparations 1 - 2 hours in advance of sexual
activity and repotted to have normal erections during sexual intercourse with the effects
lasting for up to 3 ~ 5 hours. For a stronger effect, patients were advised to take a cup of
the cooled infusion of the same preparation twice a day for three consecutive days. It has
been claimed that the effect lasts for three months before a repeat dose is necessary. No
side effects were reported by the traditional doctors.
Aqueous and organic extracts of the aerial parts of the plant were tested for the in vitro
relaxation of corpus cavernosum smooth muscle and the in vitro inhibition of the enzyme
phosphodiesterase 5 (PDE 5). The same extracts were tested in the in vivo rat model to
evaluate for the enhancement of sexual activity when compared to the control and an
increase in the number of pregnancies of female rats.
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The extracts were also screened for anticancer properties In the available anticancer
screening technology at the CSIR Bioprospecting Platform hosting a panel of three cancer
cell lines that are considered to be highly sensitive. viz. melanoma UACC62, renal TK 10
and breast MCF7.
The aim of this investigation was to isolate the bioactive compounds by bioassay-guided
fractionation.
6.1.1. Botanical aspects of Monsonia angustifolia.
The indigenous people who are using the plant and provided the information know the
plant by its South Sotho name "Mohlabakolobe". SANBI identified the plant as Monsonia
angust~fiJlia E.Mey. ex A. Rich., which belongs to the Geraniaceae family (Fig. 6.1). The
Monsonia genus was named after Lady Anne Monson who, in the eighteenth century.
investigated the use of the plant to treat dysentery. I
Picture 011 tlte /eftfrolll anullknowlI electronic source allllon tlte rigltt 1Il1l.\" tllkell at tlte greenltouse at CSIR ill Pretoria
Figure 6.1: Monsonia angust~folia in flowering state, inserted is a picture of the seeds
Known common names I of the plant are crane's bill (English), alsbossie, naaldbossie,
teebosie, assegaaibos, rabas (Afrikaans), Mokorotswana (Sotho), Remarungana (Tswana)
and Igqitha (Xhosa).
M angust~(()lia is an annual herb with wavy leaves that is found in the open grassland
throughout South Africa and it is often found by the roadside.2 The plant grows very well
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by seed germination. The species differs from other related species of the same genus by
the colour of the flowers. Without the flower, the species look identical. M angust[folia
has a distinct bell-shaped purple flower that opens up during the early morning hours.
A literature study was conducted to establish pnor art information before undertaking
further validation of the plant. It was found that the plant was not well documented for its
chemical composition and also for the therapeutic area under investigation.
6.1.2. Ethnopharmacology
Traditional doctors who provided the indigenous knowledge to the CSIR have described
the plant to be used as a sexual stimulant, blood cleanser and for the treatment of STD's.
The plant was also identified by an undisclosed source as the same as a plant used by the
Zion Christian Church (ZCC) members, who use the plant as a blood cleanser under the
common name Special.
We could not find any direct written record to support the information provided for the
treatment of erectile dysfunction. Margaret Roberts I is the only source that records the use
of this plant to treat other medical conditions:
• Heartburn - drink hot infusions ofleaves, stems and fruits (tea)
• Anthrax - apply hot infusion of plant as a skin lotion
• Blackwater disease - use the plant leaves
• Diarrhoea - drink hot infusions of plant
• Eye infections - use weak infusion of plant
• Ophthalmia - wash infection with cooled infusion of plant
• Haemorrhoids - wash skin with cooled infusion of plant
• Snakebites - drink and apply hot infusion of plant (tea) as a skin lotion
• Sores (slow healing) - apply sap/juice from stems or leaves to affected area
• Ulcers - drink and apply cooled infusions of plant as skin lotion
• Dyspepsia - drink hot infusions of leaves, stems and fruits
• Flatulence - drink hot infusions of leaves, stems and fruits
• Digestive disturbances - drink hot infusions of leaves, stems and fruits
• Varicose veins - drink and apply cooled infusions of plant as skin lotion
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It was reported that the leaf and root extracts of the M b(flora DC are used in South Africa
for diarrhea, dysentery and snakebite and an infusion of the whole plant is regarded as an
abortifacient. Several other species of Monsonia are reported to have been used in the
treatment of dysentery, typhoid fever, intestinal hemorrhage and diarrhea. 3
M. emarginata is used by the Zulu's to treat snakebites and dysentery whereas the Xhosa
and Mfengu use it the same way as M. angust(folia is used.4 Decoctions are taken for
colds and fever. The boiled roots of the plant species were drunk for rituals among the
Central Kalahari Hunter Gatherers for the treatment of anodyne. A variety of species have
been used for diarrhea, dysentery and gastric disturbances. The possible effects have been
attributed to tannins.6
Monsonia species have been used as a snake bite antidote by the Zulu's. Decoctions are
taken for colds and fever and whole plant infusions are taken as abortifacients. The plants
are also part of ingredients in medicines taken for anthrax. The leaf sap is applied to the
pustules associated with the diseases. I
6.2. PREVIOUS PHYTOCHEMICAL STUDIES
Phloroglucinol (6.1), which has antiprotozoal activity, tericin, and entericin (6.3)5 were
reported to be present in the plant genus.6 Pyrogallol (6.2) was isolated from the alcoholic
extract of M burkeana. It was reported that M niveae from the Arabian Gulf contain
saponins, coumarins, flavonoids, steroIs/triterpenes and tannins. 7 However, to our











6.3. ISOLATION AND STRUCTURE ELUCIDATION OF THE ACTIVE
COMPOUNDS
An aqueous extract mimicking the recorded traditional preparation method and an organic
extract prepared according to the standardized pharmaceutical preparation that employed a
(l: 1, v/v) mixture of methanol and dichloromethane was obtained from the ground plant
material. The efficacy was checked by testing both of the extracts for their potential to
inhibit phosphodiesterase 5 (POE 5), which limits the hydrolysis of cyclic guanosine
monophosphate (cGMP) to 5' guanosine monophosphate (5'GMP) and thereby increases
the intracellular concentrations of cGMP facilitating corpus cavernosum smooth muscle
relaxation. The organic extract exhibited a much higher inhibition of POE 5; henceforth we
proceeded with purification of this extract (Fig 6.2).
Initial liquid-liquid partitioning of the extract (see Chapter 3, liquid-liquid partition
protocol) afforded hexane, dichloromethane and water fractions. Based on POE 5
inhibition, the dichloromethane fraction showed a 20% improvement in activity compared
to the original crude extract. Repeated column chromatography on flash silica gel afforded
the isolation of five compounds that were identified as aryl naphthalene lignans 6.4 to 6.8,
which are formed biosynthetically from two phenyl propanyl (C6-C3) units. In addition
one steroid, ~-sitosterol (6.9), was also obtained.
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6.8: Retrochinensinaphthol methyl ether
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H
6.9: 13-Sitosterol
The aqueous extract had a less significant inhibition of POE 5. Fractionation of this extract
on silica gel afforded a carbohydrate disaccharide, sucrose (6.10). Sucrose has also been
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Figure 6.2: General extraction and isolation procedure
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6.3.1 Characterization of 5-methoxyjusticidin A (6.4)
5-Methoxyjusticidin A (6.4) was isolated as a white amorphous solid. A molecular ion
peak at m/z 425.4 corresponding to [M+ It in the positive LRESIMS and at m/z 424 in
AutoSpec ETOF Et which are both pointing to the molecular formula C23H200g. The UV
spectrum was obtained from a diode array detector (DAD) and absorptions were observed
at A365, 263 and 237 nm.
In the IH NMR spectra of 6.4 (Table 6.1) the presence of a methylenedioxy group, OH 6.02
(IH, d) and OH 6.07 (l H, d) with a very small coupling ofJ 1.3 Hz was observed. The other
methylene singlet observed at OH 5.41 is characteristic of the methylene group found in a
penta-lactone ring of lignans. Four singlets assigned to the methoxyl groups were observed
at OH 3.74, 3.95, 3.97 and 4.01. An aromatic proton singlet was observed for H-8 at OH
6.94. Three aromatic protons were found exhibiting the or/ha coupling (J:= 7.9 Hz) and
me/a coupling (J:= 1.6 Hz) which are consistent with a 1,3,4 trisubstituted phenyl group.
The 13C NMR spectra showed 23 resonance signals. Four signals could immediately be
assigned to the four methoxyl carbons resonating at oe 55.8, 61.4, 62.4, and 62.0. The
multiplicity of the other carbon signals was obtained from DEPT spectra that showed 10
protonated carbon signals, two of them being CH2 and four were CH, apart from the four
that were already assigned as methoxy groups. There was also evidence of a carbonyl
group at 8e 169.5, which is characteristic of the lactone functionality in the strained five-
membered ring. C-3 was also not found in the aromatic region and was assigned to the
methylene group at oe 66.5 attached to the carbonyl forming a lactone. The structure was
confirmed by the >IJeH correlations observed in a HMBC experiment.
5-Methoxyjusticidin 6.4 was previously isolated by Siani e/ al. from the wood of Protium
un~foliolatunl In this article, some of the NMR signals were not assigned correctly (C-9,
C-9a, C-8, and C-8a) and we were able to assign them with the aid of 20 experiments. The
author acknowledged the wrong assignment and thus the assignment we propose can be
taken as correct.
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bH (J in Hz) >IJCH correlations
SAl (s) C-I, C-4, C-9a





2' 101.2 6.02, 6.07 (d, 1.4;d, lA) C-7a',C-3a'
3a' 147.6
4' 110.6 6.78(d,l.3) C-6',C-9,C-7a'
5' 128.5
6' 123.6 6.75,6.76 (dd, 1.6,7.9) C-4" C-9, C-7a'
7' 108.3 6.92,6.94 (d, 7.9) 5', C-3a'
7a' 147.5
* I3C NMR (125.7 MHz) and 'H NMR (500 MHz)
H CO 73
6.4
Figure 6.3: Key correlations obtained from HMBC data
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6.3.2 Characterization of justicidin A (6.5)
This compound was isolated as white amorphous flakes. The I H MR spectrum of 6.5 was
similar to that of 6.4. The main difference was that the spectrum of 6.5 exhibits the
presence of only three methoxy groups (OH 3.79, 4.04, 4.11) instead of four as for 6.4. One
methoxy at C-5 was replaced by a proton resonating at OH 7.52. The absence of observed
coupling between the two protons resonating at OH 7.52 and 7.04 suggests a para
relationship between them. The methylene signal at OH 5.51 which forms part of the
furanone ring was still present as was the three aromatic protons that formed the I, 3, 4-
trisubstituted phenyl group. A pair of proton doublets with very weak coupling (OH 6.02
and 6.06 with a J HH value of 0.9 Hz) was observed for the methylenedioxy substituent.
Twenty two 13C NMR signals were observed which is in compliance with one less
methoxy group. The three methoxy groups were assigned at Oc 55.8, 56.1 and 59.7. A
carbonyl signal was observed downfield at Oc 169.5. The methylene group forming part of
the furanone ring was assigned at Oc 66.6. The methylenedioxy carbon signal was found at
Oc 101.2. The rest of the carbon signals were found to support the structural framework
with the same substitution pattern as for 5-methoxyjusticidin A (6.4).
lusticidin A (6.5) showed a molecular ion peak of m/z 395.4 in ESIMS positive mode
corresponding to [M+1r and the molecular formula C22HI807. In the DV spectrum of this
compound as obtained from a diode array detector has a strong absorption maximum at
261. 7 nm. This compound is widely distributed within the different species of Justicia and
it has been widely studied before for antiviral9 , anti platelet'O 11 and cytotoxic 12 activity
but not for the activity reported here.
Published NMR data for justicidin A 13.14 supported the structural assignment ofjusticidin
A (6.5).
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Table 6.2: NMR data ofjusticidin A (6.5) in CDCb
Dept & HMBC
C OC HMQC OH (JHH in Hz) COSY >IJCH correlations
I 169.5 C=O




5 100.6 C 7.52 6-0CH;
6 151.6 C
7 150.4 C




4-0CH; 59.7 OCH; 4.11 C-4
6-0CH; 56.1 OCH; 4.04 C-6
7-0CH; 55.8 OCH; 3.79 C-7
2' \01.2 CH 2 6.02,6.06 (d, 1.0) C-7a', C-3a'
3a' 147.5 C
4' 110.8 CH 6.8 (5) C-6', C-9, C-7a'
5' 128.5 C
6' 123.6 CH 6.76, 6.78(dd, 7.9, 1.4) H-T C-4', C-9, C-7a'
l' \08.2 CH 6.92,6.94 (d, 7.9) H-6' C-5', C-3a'
7a' 147.4 C
* I3C MR (125.7 MHz) and 'H NMR (500 MHz)
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6.3.3. Characterization of chinensinaphthol (6.6)
Compound 6.6 is commonly known as chinensinaphthol and it was previously isolated
from Justicia procumbens and tested for antiplatelet properties as documented by Z. Horii
et al 1968. 15
A mass to charge ratio (m/z) of 381.4 observed in LRESIMS in positive mode was
assigned to the molecular ion peak [M+1t, which is in agreement with the formula
C2J H 160 7. The UV maximum plot of this compound from the DAD spectrum showed
absorptions at 322.0, 266.4 and 228.8 nm, which is characteristic of aryl naphthalene
molecules.
Compound 6.6 was purified by flash silica gel chromatography and visualization under
long range UV 254 nm gave a purple coloured spot and a very intense blue fluorescent
color when viewed at 366 nm. It was obtained as a white amorphous substance that could
not be re-dissolved in a single solvent only. Thus, it was dissolved in a mixture of CDCl3
and MeOH-d4 for NMR experiments and the obtained data are collated in Table 6.3.
IH NMR data showed a singlet at 011 5.35 which can be assigned to the lactone methylene
group and a resonance at OH 6.15 (s, H-l 0) that is characteristic of a methylenedioxy group,
and two methoxyl groups appeared as singlets at 811 3.71 and 3.84. In the previous two
structures (6.4 and 6.5), the methylenedioxy groups were attached to the C ring and the
methoxy groups to the A ring. However, >IJCIl correlations observed in the HMBC
experiment, indicated that in this compound, the methylene group is on the A ring and the
methoxy substitutents on the B ring. The three aromatic C ring protons formed an ABX
system characteristic of trisubstituted phenyl as it was observed for the lignans 6.4 and 6.5.
These protons resonated at 8H 6.83 (H-2', d, 8.24), 6.77 (H-6', dd, 2.07 & 8.03), 7.05 (H-5 ',
d, 8.24) and their coupling was supported by the COSY 20 correlations.
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Table 6.3: NMR data* of Chinensinaphthol (6.6) in CDCI:; & CD:;OD
Dept & HMBC
C 0(' HMQC 011 (J in Hz) COSY >IJnt correlations
I 169.4 C=O
.,




5 97.9 CH 7.61 (s) C-8a, C-4, C-7
6 148.6 C
7 148.0 C




10 101.9 CH2 6.15(s) C-6, C-7
I' 127.5 C
2' 114.2 CH 6.83 (d, 2.1) H-6' C-4', C-6', C-9
3' 148.2 C
4' 148.3 C
5' 111.2 CH 7.05 (d, 8.2) H-6' C-1', C-3'
6' 122.5 CH 6.77 (dd, 2.1 & 8.0) H-5" H-2' C-2', C-3', C-9
3'-OCH:; 55.5 OCH:; 3.71 (s) C ."-.)
4'-OCH:; 55.4 OCH:; 3.84 (s) C-4'
* DC NMR (100.6 MHz) and JH NMR (400 MHz)
J3C NMR spectra data with 21 carbons supported the proposed structure 6.6 and the mass
spectrum data obtained. The carbonyl C-1 of the lactone ring and the methylene group C-3
in the same ring were assigned resonances at Oc 169.4 and 66.4 respectively. Other
important signals were the two methoxy groups that resonated at Oc 55.4 and 55.5 and the
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methylenedioxy C-IO that resonated at be 101.9.
On the basis of the spectral data and the supporting correlations observed in 2D NMR
experiments, compound 6.6 was identified as chinensinaphthol.
6.3.4. Characterization of suchilactone, 6.7
6.7
Crystalline and yellowish 6.7 was isolated from the methanol-dichloromethane extract of
M angustifolia and its spectral data is collated in Table 6.4. The structure was deduced
with the help of the 2D NMR correlations that provided information to the C-H
connectivity pattern. The proposed structure was also confirmed by comparison to
literature data. 16
ESIMS (+) of compound 6.7 showed a molecular ion peak of m/z 368 which agrees with a
molecular formula of C2I H200 6. In the mass spectrum, fragments were observed at m/z
151, which was assigned to the fragment 6.7.1 and at m/z 217 assigned to the fragment
6.7.2.
Two methoxy groups were observed in the IH NMR spectrum at bH 3.84 and 3.86 as
singlets. In contrast to the other compounds where only one 1,3,4-trisubstituted phenyl ring
was observed, in the 'H NMR spectrum of 6.7, a second set of ABX protons were present.
Additionally, an olefinic proton was observed at bH 7.50.
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Table 6.4: NMR data* of Suchilactone (6.7) in CDCl]
DEPT& HMBC
C be bH (J in Hz) HMQC COSY >IJcH correlations
2 172.5 C=O
3 126.1 C
4 40.1 3.75 (m) CH H-T', H-5 C-8', C-2, C-I"
5 69.8 4.26 (m) CH1 H-4 C-T', C-3, C-2
2' 101.7 6.02 (d, 1.9) CH1 C-3a', C-7a'
3a' 148.4 C
4' 126.3 7.08 (s) CH C-6" C-7a', C-8'
5' 128.3 C H-6'
6' 108.5 7.06 (s) CH H-7', H-4' C-4', C-8', C-7a'
7' 108.8 6.87 (dd, 8.5, 1.9) CH H-6' C-5', C-3a'
7a' 149.2 C
8' 137.2 7.50 (d, 1.9) CH C-4', C-6', C-2, C-4
1" 130.4 C
2" 120.9 6.73 (dd, 2.0,8.2) CH C-4", C-6", C-7"
3" 149.2 C
4" 148.1 C
5" 111.5 6.85 (d, 8.1) CH H-6" C-I ", C-3"
6" 112.2 6.69 (d, 2.0) CH C-2", C-4", C-7"
7" 37.7 2.63 (dd, 14.13,4.31); CH1 H-4 C-3, C-5, C-2", C-6"
3.01 (dd 14.12, 10.02)
4"-OCH 3 55.9 3.86(s) OCH 3 C-4"
3"-OCH3 55.9 3.84 (s) OCH 3 C ""Ill-..l
* IJC NMR (100.6 MHz), 'H NMR (400 MHz)
From the COSY correlations it was observed that the protons at H-4 couples with those
protons at positions H- 5 and H-7". These key correlations are shown in Fig 6.4 and they
are represented by arrows in red. The other correlations observed were H-6' to H-4' and H-
7' and also in the C ring there was a strong correlation between H-5" and H6".
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6.7
Figure 6.4: Key COSY correlation of compound 6.7
The I3C NMR of compound 6.7 showed 21 carbon signals with two methoxy groups
overlapping at be 55.9. The carbonyl in the lactone ring resonates at be 172.5 and the
methylene group in the same ring appears at be 69.8. The exocyclic double bond of the
lactone ring showed resonance peaks at be 126.1 and 137.2 for the carbons at C-3 and C-8',
respectively. The methylene carbon at C-7" was assigned to the signal at be 37.7. The
methylenedioxy group at C-2' showed its resonance peak at be 101.7. The DEPT spectrum
was used to assign the multiplicity of the carbon resonances. Two overlapping methoxy
peaks, three CH2 and eight CH peaks, leaving the remaining eight carbon signals to be
assigned as quaternary carbon atoms.
6.3.5. Characterization of retrochinesinaphthol methyl ether, 6.8
Compound 6.8 (Cn H1s0 7) was identified as retrochinesinaphthol methyl ether.
17 A mass-
charge ratio m/z 395.4 [M+It (ESIMS) was obtained which supports the molecular
formula of C22H 1S0 7. The structure of the compound is similar to that of 6.6 with the
difference that the methylene and the carbonyl groups of the lactone ring are swopped
around and that the hydroxyl group in position C-4 was now replaced by a methoxy group.
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Table 6.5: NMR data* of compound 6.8 in CDCI3
Dept & HMBC
C 8c HMQC 8H (J in Hz) COSY >IJCII correlations
I 169.1 C=O




5 102.2 CH 6.98 (s) H-8 C-7, C-8a, C-4
6 148.2 C
7 150.8 C




10 101.8 CH 2 6.06 (s) C-6, C-7
9-0CH 3 63.5 OCH 3 4.31 (s) C-9
I' 128.5 C
2' 112.6 CH 6.79 Cd, 2.0) H-6' C-4', C-6', C-4
3' 149.4 C
4' 149.0 C
5' \\1.8 CH 6.99 (d, 8.0) H-6' C-I', C-3'
6' 121.9 CH 6.84,6.86 (dd, 2.0, 8.0) H-5', H-2' C-2', C-4', C-4
3'-OCH3 56.1 OCH3 3.86 (s)
4'-OCH3 56.0 OCH 3 3.96 (s)
* I3C NMR (100.6 MHz) and JH NMR (400 MHz)
C ~,-j
C-4'
Comparison of the IHand I3C NMR data of this compound (6.8) with those reported in the
literature'7 and observed for 6.6 led to the assignment of compound 6.8 as
retrochinesinaphthol methyl ether.
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6.3.6. Characterization of p-sitosterol (6.9)
The structure of compound 6.9 was assigned as ~-sitosterol by comparison (TLC, GC, MS
and NMR) with the compound isolated from Pergularia daemia (section 5.3.2) and with a
commercial sample of ~-sitosterol obtained from Sigma Aldrich.
Table 6.6: NMR data* of ~-sitosterol (6.9) in CDC!]
Observed Literature
C oe Dept OH (J in Hz) be bH (JHH in Hz)
1 37.2 CH2 1.89 37.1 1.05m: 1.83m
2 31.6 CH! 1.56 31.5 1.82m: 1.48m
3 71.8 CH 3.50(1 H,m) 71.7 3.48m
4 42.4 CH 2.26 42.2 2.28m
5 140.7 C 140.8
6 121.7 CH 5.32(IH, d, 5.0) 121.7 5.32(d, 5.0)
7 31.8 CH 2 1.53 31.7 1.53m
8 31.7 CH 1.93 31.7 1.90m
9 50.1 CH 0.98 50.0 0.87m
10 36.5 C 36.3
II 21.1 CH 2 1.52 20.9 1.43m
12 39.8 CH 2 2.03 39.6 1.13m; 1.99111
13 42.3 C 42.7
14 56.8 CH 0.99 56.7 0.94111
15 24.3 CH 2 1.61 24.1 1.13111; 1.61m
16 28.2 CH! 1.85 28.1 1.35111; 1.86111
17 56.1 CH 1.12 55.9 1.06m
18 I 1.8 CH] 0.64 (5) 11.7 0.655
19 19.3 CH] 0.93 (5) 16.7 1.005
20 36.1 CH 1.37 36.0 1.32111
21 19.3 CH] 0.90 (d, 7.0) 19.2 0.92 (d, 7.0)
22 33.9 CH 2 1.35 33.8 0.99111; 1.26111
23 26.1 CH! 1.23 25.9 1.12111
24 45.8 CH 0.96 45.7 0.95111
25 29.2 CH 1.70 29.0 1.62111
26 19.8 CH] 0.82 (d, 7.0) 18.9 0.88 (d, 7.0)
27 19.0 CH] 0.81 (d, 7.0) 18.6 0.77 (d, 7.0)
28 23.1 CH! 1.27 22.9 1.20m
29 11.9 CH] 0.84 (t, 7.0) 11.8 0.82 (t, 7.0)
* 500MHz for IH NMR and 125MHz
The mass spectra data was observed giving the molecular ion peak m/z at 415 and a base
line peak at m/z 414 [M-Ht as determined by the AutoSpecETOF operating at EI+. The
observed molecular ion is in agreement with the proposed molecular formula of C29H300.
Further confirmation of the mass spectral data was obtained for the ESIMS· operating in
the negative ion mode which gave a molecular ion peak of 459.2 that was attributed to the
chelating of this molecule with two sodium adducts [M+2Na]".
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6.3.7. Characterization of sucrose (6.10)
A disaccharide 6.10 was obtained as clear and crystalline compound and by comparison
with the compound from Pergularia daemia (section 5.3.1) and commercial material,
identified as sucrose. 18 The mass spectra data supported the proposed structural formula of
Cl2HnOll with a base peak of m/z 341 [M-Hr obtained in the negative ion mode on
ESIMS.
Table 6.7: NMR data of the sucrose (6.10)
Sucrose (6.10)
Isolated compound" Literature 19;'
C (le (lH (JHH, in Hz) (le (lll
I 92.4 5.12 93.20 5.41
2 72.3 3.13 72.14 3.56
3 73.5 3.61 73.68 3.76
4 70.5 3.07 70.31 3.86
5 73.4 3.42 73.44 3.47
6 61. J 3.58 61.24 3.81
I' 62.7 3.58,3.35 (2H) 62.46 3.67
2' 104.7 104.71
3' 77.7 3.83 77.51 4.21
4' 75.0 3.72 75.09 4.05
5' 83.2 3.52 82.42 3.89
6' 62.7 3.49 63.44 3.83
" Data obtained in DMSO, L'C at 100.5 MHz and 'H at 400 MHz
# Data obtained in [),O. "c at I00 MHz and '1-1 at 400 MHz
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6.4. QUANTIFICATION OF M. ANGUSTIFOLIA EXTRACTS BY HPLC-MS
As part of the investigation on this plant for its use as a treatment for erectile dysfunction
and enhancing sexual drive, analytical methods for the validation of the extract were
developed.
The extract was chromatographed on reverse phase C 18 column in order to obtain a
chemical profile on the LCMS. The solvent gradient used was composed of a mixture of
acetonitrile and water as tabulated in Table 6.8.
Table 6.8: Alliance 2690 HPLC pump gradient and UV/MS event conditions
Time (min) % Water %ACN Flow Rate
0.00 90.0 10.0 1.000
61.00 20.0 80.0 1.000
64.00 0.0 100.0 1.000
75.00 0.0 100.0 1.000
75.10 90.0 10.0 1.000
90.00 90.0 10.0 1.000
Column temperature 40°C
Mass range scan 50 to 2000
Wavelength scan (nm) 193.00 to 400.00
The extract was chromatographed at concentrations of 5000 ppm and 25 III was injected.
The chemical fingerprint obtained for the methanol-dichloromethane extract is shown in
Fig. 6.5.
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Figure 6.5: UV and ESIMS+ chromatogram of the methanol-dichloromethane extract
The extract demonstrated the presence of several compounds but the most UV absorbing
compounds are concentrated in the region between 30 and 45 minutes. In light of the
obtained results, continuation of this work in order to identify the active ingredients was
done by means of liquid-liquid partition, column chromatography purification and
characterization by NMR spectroscopy experiments. Five lignan compounds, 6.4 to 6.8
were isolated and they were shown to be present in the original methanol-dichloromethane
extract by HPLCMS chromatography experiments. Figure 6.6 lists the five chromatograms
as obtained for the five compounds.
112
Chapter 6: Mansonia angustilolia and pharmacology







0.0' i i '''''._-~'''F'-.-;--:--:-







2~97 it , ". I I ~. I'~·~
15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00 65.00
Compound, 6d 38.42,
:::> 10e+1~«
" 53.!~ ..__~7,~00· r"
,1,,-
i~I i I (f , r~~,~~r







----.J \....., I'l i .'









I i I i
15.00 20.00 2500 30.00 35.00 4000 45.00 50,00 5500 60.00 65.00
MeOH/DCM extract 31.97 38.17
1.0e+2i I I35.90 ,40.75 92I:::> j .! ~ ~I '\ 4\«
1482 " 3512 i\ '~J\'::,OO~ I· 1 i 1 ii l >,,!,\?, 1 "I ·1 i " ,...... Time
1500 20.00 25.00 3000 35.00 40.00 4500 SO.OO 5500 60,00 65.00
Figure 6.6: DV chromatograms of the five lignans isolated from the aerial parts of M
angusltfolia. Compounds 6c = 6.4, 6d = 6.5, 6e = 6.6, 6f= 6.7 and 6g = 6.8.
It was very clear by looking at the DV plots of the compounds against the extract in Figure
6.6 that the extract contained all of the compounds. The chromatogram also shows that
there are still a few DV absorbing compounds that were not yet isolated, but the scope of
this kind of work does not form part of this study and will be repOlied elsewhere. The DV
chromophores and the mass spectra of each of the compounds are pasted in Figure 6.7,
confirming the presence of the compounds. It is worth noting that each compound is shown
to absorb at a high DV range which is the long range spectra visible at 366 nm. These
compounds appeared as blue spots of varying intensities at this wavelength. The DV
chromophores also show that the compounds are DV absorbing at the UV Visible region at
wavelength of 254 nm. The compounds appear purple-pink at this wavelength. AII
compounds are shown to absorb from between 257 to 263 nm. Their molecular weights
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Figure 6.7 continues: UV/MS chromophores of the isolated lignans 6.6 and 6.7 as























Figure 6.7 continues: UV/MS chromophores of the isolated lignans 6.8 as obtained from
the LCMS
6.4.1. Development of the standard curves
In order to quantify M. angustifolia extracts, standard curves were developed for each of
the five lignan compounds (Fig. 6.8). This was done by the chromatography of each of the
compounds at five concentrations representing five serial dilutions ranging from 50 to 250
ppm. The chromatograrns were then integrated to obtain the area percentage of each peak.
To demonstrate this result, the methanol-dichloromethane extract was integrated and the
chromatogram is shown in Fig. 6.9. One of the chromatograms is showing the area
percentage table based on all the detected peaks. The result from this type of table for each
of the compounds is collated and plotted into a graph to produce the standard curves.
Standard curves were developed for each of the compounds and are displayed. The result
of these curves is the opportunity to calculate the quantity of each compound in the
original extract based on the peak area of the compound from the integration of the
chromatogram.
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Note that one of the values for a concentration at lOO ppm for compound 6.4 was not
included in the plotting of the standard curve because its peak area lies out of the
confidence limit. This set back must be due to an experimental error on sample
preparations.
The compound was analyzed at three concentrations only; there was a problem
experienced with the solubility of the extract which required the addition of a few drops of
acetone when dissolving the compound.
























Standard curve for justicidin A (6.5)
y =4E+06x + 99591
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Figure 6.8: Standard curves of the compounds
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Standard curve of compound retrochinensinaphthol (6.8)
y =4E+06x - 88706
R 2 = 0.996
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Determination of the concentration of each compound in the extract
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Figure 6.9: Integrated DV plot of the methanol-dichloromethane extract
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6.5. BIOLOGICAL ACTIVITY
In order to validate the use of the plant for the treatment of erectile dysfunction and the
enhancing of libido, the prepared organic and aqueous plant extracts were evaluated in the
available and accessible biological assays. These extracts were prepared as illustrated in
Fig 6.3.
6.5.1. In vivo mating frequency and pregnancy model (MFM)
In vivo assaymg of the combined aqueous (sample A) and organIc I: 1 methanol-
dichloromethane (sample B) extracts (4:6 w/w mixture, referred to as CIR 40 in Tables 6.9
and 6.10) in a sexual activity, mating frequency/pregnancy model (MFM) provided the
first scientific evidence for the efficacy of the plant. The extract mixture was administered
orally to 3 male rats at a dose of 300 mg/kg for 8 consecutive days. Three dosed rats and
three placebo-fed male rats were each paired with six female rats. Sexual activity was
recorded by video surveillance during the nocturnal period i.e. from 17hOO to midnight.
Differences are considered significant at P<0.05. The vehicle control substance (water)
was dosed orally at 10 ml/kg per animal. The extract mixture exhibited a significant
increase in mating frequency and the number of pregnancies. The results obtained from the
bioassay are shown in Tables 6.9 and 6.10.
Table 6.9: Results obtained in the sexual activity, mating frequency assay
Treatment Group Mating frequency (individual groups) Total Mean±SEM
Number
Day Day Day Day Day Day Day
2 3 4 5 6 7 8
Vehicle I 13 0 0 0 43 1I I 68 82.0±10.7
(Distilled 2 42 0 31 I 0 0 I 75
water) 3 38 10 5 0 17 1I 22 103
Test 1 39 75 50 48 87 2 0 301 243.0 ±55.5
substance 2 6 118 56 74 41 0 1 296
(CIR 40) 3 10 9 I1 55 12 17 18 132
The extract mixture demonstrated an increased mating frequency as shown by the high
mean number of mounts 243 as compared to the vehicle control where only 82 mounts
were counted. The difference in the number of mounts between the extract fed rats and
those given a placebo is almost three fold. This result proves the capability of the extract to
enhance the libido of the male rats that were fed with the extract mixture. The model is set
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up such that after 8 days the female rats are inspected for the following two weeks for
pregnancy and the result are collated in Table 6.10. A much higher number of pregnancies
were observed in the groups where the males received the plant extract.
Table 6.10: Results obtained from the sexual activity, pregnancy assay
Treatment Group Number Individual Number of Total number of Mean±SEM
pre2nancies pre2nancies
Vehicle I 3 8 2.7 ±0.3
(Distilled 2 2
water) 3 3
Test 1 5 14 4.7 ± 0.3
substance 2 5
(CIR 40) 3 4
6.5.2 In vitro phosphodiesterase 5 inhibition
In order to establish the possible mode of action of the plant for the activity observed in the
rat model, the extracts were screened in vitro for inhibition of the enzyme
phosphodiesterase 5 (POE 5). Inhibition of PDE 5 limits the hydrolysis of cGMP to 5'GMP
and thereby increases the intracellular concentrations of cGMP which then concomitantly
facilitates the relaxation of the corpus cavernosum smooth muscle. A combination of the
aqueous (sample A) and organic (sample B) extracts in a 1: 1 (w/w) ratio was assayed for
the in vitro inhibition of PDE 5. The mixture exhibited a significant inhibition (80%) at
100 ppm (Table 6.11).
When the orgamc (sample B) and the aqueous extracts (sample A) were assayed
separately, the organic sample B exhibiting the highest inhibition PDE 5 (96%).
Partitioning of this extract yielded three fractions of different polarities, the hexane
(Sample 0), dichloromethane (Sample C) and water (Sample E) fractions. All three
samples showed a significant inhibition of the enzyme with the highest inhibition observed
for the dichloromethane fraction (sample C).
Table 6.11: Summary of results demonstrating PDE 5 inhibition
Test sample Concentration % Inhibition of PDE 5
ug/ml
Sample A Aqueous 100 68
Sample B I: I MeOH/DCM 100 96
Sample A + B (I: 1) Aqueous + organic 100 80
Sample C DCM 100 101
Sample D Hexane 100 62
Sample E Water 100 85
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6.5.3. In vitro relaxation of the pre-contracted rabbit cavernosum smooth muscle
Since the inhibition of the PDE 5 concurrently induces the relaxation of the smooth
muscles, samples A and B were also tested for their relaxation effect on the strips of the
rabbit corpus cavernosum smooth muscle pre-contracted with 2 ml of Krebs-PSS (17.8
mg/ml). The contraction/relaxation is reported relative to sildenafil tested at 78 ng/ml.
Both extracts were observed to relax the rabbit cavernosum smooth muscle significantly
and the results are shown in Table 6.12. The extracts tested at 2.6 mg/ml showed a 50%
relaxation but at this point it was not clear whether the activity is due to cytotoxicity.
Viagra (sildenafil) was reported to facilitate 100% relaxation of the same smooth muscle at
a concentration of 1.8 x 10-5 mg/ml which is a thousand fold more potent than the test
extract. This result suggests that the extracts act by inhibiting the PDE 5 enzyme thereby
decreasing the intracellular hydrolysis of cGMP to 5'GMP and this in turn stimulates the
relaxation of the smooth muscles thereby allowing the easy flow of blood into the relaxed
penile.
Table 6.12: The rabbit corpus carvernosum smooth muscle relation and cytotoxicity
results of the extracts.
The samples 1I'ere lesled 1I'IIh reference 10 Sildenafil or I IGgra Ihat sh01l'ed 100% smoolh muscle relaxallOn al 1.8.\ 10' mg ml
Concentration Relax (R) / Contraction (C)% Cytotoxicity, CHO
Test sample
of sample mg/ml (standard deviation in brackets) assay ICso !!g/ml
Sample A 2.6 50 (0) R >100
Sample B 2.6 46 (7.1) R 18.6
,. ..
6.5.4. Activity of isolated compounds
The five lignans (6.4 to 6.8) isolated from the organic extract were tested for relaxation of
strips from the basal area of the rabbit corpus cavernosal precontracted by phenylephrine
(3 1-!M). A test substance (30 1-!M) that induces relaxation by 50 percent or more (~50%)
within 5 minutes, relative to the control 0.3 1-!M sodium nitroprusside response, indicates
significant relaxation. These compounds were also screened for PDE 5 inhibition at a
concentration of lOflM (Table 6.13).
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Compound No. inhibition at 10
relaxation at 30 f..lM
(CHO) ICso formula
f..lM (!lg/ml)
6.4 11 62 9.0 CnH~o08
6.5 22 0 1.0 C~~H IS07
6.6 29 75 28.5 C~IH1607
6.7 35 71 >100 C~IH~o06
6.8 53 57 >100 C2~H IS07
0 : , 3 . -I taglG sholled 100% lelmallOIl a/1.8.\ 10 pg'lI1lol an le w lalue of-/.1.\ 10 ,l/,t/fol PDI.) mluhl/lOn
"le50 values '.SI. 0 are considered /0 he cyroroxic in CHO rests
'PDE 5 inhibirion and sl11oo/h l11uscle relaxarionll'ere considered sign!(icanr or ?:.50% values
Compared to the synthetic sildenafil that showed 100% relaxation at 1.8 x 10-2 Ilg/ml and
an ICso value of 4.1 x 10-
3 IlM for POE 5 inhibition, these compounds are at least a
thousand fold less active. The most significant inhibition of PDE5 was displayed by
retrochinensinaphthol methyl ether (6.8). Four of the compounds, 6.4, 6.6, 6.7 and 6.8,
exhibited a significant relaxation of the smooth muscle at concentrations of 30 IlM for each
compound.
Rabbit corpus cavernosum smooth muscle relaxation was observed for compounds 6.4,
6.6,6.7 and 6.8 with the lowest percentage of the smooth muscle relaxation of 57% and the
highest being 75%. Only one compound, justicidin A (6.5), exhibited minimal POE 5
inhibition and nil efficacies for smooth muscle relaxation at the test concentrations. Three
compounds 6.4, 6.6 and 6.7 showed a significant smooth muscle relaxation alongside a
weak inhibition of the PDE 5. Retrochinesinaphthol methyl ether (6.8) is the only
compound with a significant result of both the inhibition of POE 5 and relaxation of the
smooth muscle that is more than fifty percent. There are no obvious structural features in
the lignans 6.4 - 6.8 that can be associated with the activities of the compounds.
These findings suggest that the extract act by synergistic effect of its component
compounds through the mechanism of the blocking of the PDE 5 thereby causing the
relaxation of the corpus cavernosum smooth muscle.
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6.5.5. Cytotoxicity of compounds and extracts on CHO cells
The compounds and the extracts were tested for toxicity against the mammalian Chinese
Hamster Ovarian cells (CHO) and the results are collated in Tables 6.12 and 6.13. A test
substance was considered cytotoxic if it exhibits an IC50 values :S1.0 llg/ml. Emetine with
an IC50 value of 0.05 llg/ml was used as a standard.
The aqueous extract was tested to evaluate whether this form of formulation used
traditionally by the traditional healers is not toxic. The organic extract was prepared as an
innovative step to extract more of the active compound(s). The organic extract did not
exceed the limit set for cytotoxicity, but with an IC50 of 18.6 Ilg/ml, may contain some
cytotoxic compounds. No toxicity was observed for the aqueous extract.
Two compounds suchilactone (6.7) and retrochinesinaphthol methyl ether (6.8) were non-
cytotoxic at a concentration of 100 Ilg/ml. The most cytotoxic compound, justicidin A
(6.5), did not display any relaxation of the rabbit smooth muscle or a significant inhibition
of the POE 5 enzyme at the test concentrations (Table 6.13). Looking at the structures of
the compounds, the cytotoxicity of 6.5 might be due to the substitution of one of the
methoxy group by hydrogen atom. The toxicity of this compound also proves that the
activity observed for the compounds in the inhibition of the PDE 5 and relaxation of the
smooth muscle might not be due to toxicity since justicidin A (6.5) exhibited no activity in
these two assays.
6.5.6. Anticancer activity of extracts and compounds
The plant aqueous sample A and organic sample B extracts were also evaluated for
anticancer activity in the available CSIR in-house cancer screen against the melanoma,
renal and breast cancer cell lines (Table 6.14). Only the sample B exhibited a moderate
activity with selectivity for the melanoma cell line. This extract was sent to the NCI for
further evaluation in their panel of 60 cell lines.
124
Chapter 6: Monsunia angllsti(olia and pharmacology
Table 6.14: Results obtained in anticancer screening of the extracts and compounds
AetlVIO' crtlerlll: Tolal groll'lh Inl1lhillOn (TGI) > I) ppm " )() fJfJm (ll'eakly aell1'e): TGI '6.2) 10 I) ppm for 111'0 10 Ihree eellllnes
(moderme aelivil)): TGI < 6.25 for NO 10 Ihree eel/lines (polenl aelivil)~
Compound /Sample
Result Effective concentration, TGI
evaluation +01(x 10 Ilg/ml or ppm)
Sample A Weak 5.00






.. , - - -
The two compounds 6.4 and 6.5 showed moderate to potent selective activity for the
melanoma cell line. Compound 6.4 passed the crucial evaluation against the NCI database
of compounds that have been tested for antitumour activity. This compound was tested in
the in vitro 60 cell lines at a minimum of five concentrations at 10 fold dilutions (Fig. 6.9,
6.10). A 48 hour continues drug exposure protocol was used and a sulforhodamine B
(SRB) protein assay was used to estimate the cell viability or growth. The NCI finding was
that the compound did not exhibit the anticancer activity at the minimum potency
concentration range they use for their screening protocol. This minimum concentration is
based on some of the drugs already available and patented for use in chemotherapy. Thus
no further work is to be done on this compound unless structural modifications to enhance
the cytotoxic activity are considered.
5-Methoxyjusticidin (6.4) exhibited an average log TGI of - 4.28 (i.e. TOI = 5.248 x 10-5
M). The NCI clinically tested the compound etoposide2o and they found an average TOI of
3.45x10-5 M.
In regard to cytotoxicity, no fUlther work will be done on this compound. Structural
modifications to enhance the cytotoxic activity may be considered.
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Figure 6.10: Mean graphs representation of the Nel antitumor screenlllg results for
compound 6.4
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Figure 6.11: Dose responds curves of the anticancer screening results of compound 6.4
from NeI 60 cell line screen.
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6.5.7. Antibacterial activity
Sample B was the highest contributor to the POE 5 activity, thus this extract was chosen
for the evaluation of the antibacterial properties of the plant. The crude organic extract was
resuspended in a small amount of DMSO and made up to a concentration of 20 mg/ml
concentration with water.
Bioautography was performed as a supplementary qualitative analysis of the presence of
antibacterial compounds. In this technique, the samples were loaded and separated on a
thin layer chromatography (TLC) plate, and after removal of eluant, sprayed with a
suspension of Staphylococcus aureus. After overnight incubation, the plate was sprayed
with a tetrazolium salt to identify the presence of antibacterial compounds in the samples.
These active compounds appeared as white spots (no bacterial growth) on a pink
background of dividing bacteria. The organic extract, sample B, displayed noticeable
antibacterial activity in this assay. Bioautography was done on TLC plates using polar
(ethyl acetate: methanol: water, 45:5:4.4 v/v/v) or non-polar (hexane: ethyl acetate, 2: I
v/v) solvent combination and thereafter sprayed with a suspension of Staphylococcus
aureus.
The non-polar solvent system did not move the active compounds from the origin. There
appeared to be only one major antibacterial compound present in the extract when using
the polar solvent system or at least the TLC separation method did not separate the
components.
Table 6.15: Minimal Inhibitory Concentrations (MIC) of samples against test bacteria
Sample MIC (mg.mr')
E. coli E·faecalis P. aeruginosa S. aureus
Sample B >5 1.25 >5 0.032
A microplate serial dilution method by Eloff21 was used to quantify the antibacterial
activity of extracts. The extract was screened against the bacteria, Escherichia coli,
Enterococcus faecalis, Pseudomonas aeruginosa and Staphylococcus aureus, and
displayed a noticeable antibacterial activity in this assay (Table 6.15). The extract had a
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high activity against S. aureus and this result was corroborated by the bioautography data
using only this pathogen. Because only S. aureus was sensitive to the extract tested,
bioautography was not carried out with other pathogens.
6.6. CONCLUSION
The plant Mansonia angustt/alia is traditionally used for the treatment of erectile
dysfunction problems and also to enhance male and female libido. The extracts of M.
anguslt(olia were scientifically validated for the reported claim in in vivo and in vitro
models. Activity was shown for the methanol-dichloromethane extract (1: 1, v/v) as
compared to the aqueous extract which is the preferred preparation used by the traditional
healers for the treatment of erectile dysfunction problems. The extracts of M. anguslt(olia
also showed anticancer and antibacterial properties.
For the treatment specific to the enhancement of libido, the extract mixture (organic and
aqueous) was tested in the in vivo sexual activity, mating frequency/pregnancy model
(MFM) which is a measure of male libido. The extract mixture exhibited a significant
increase in mating frequency (243 mounts) as compared to the vehicle control (82 mounts).
Together with the number of pregnant rats (14) as compared to the vehicle control (8), the
extract has clearly demonstrated increased male libido. This result was considered
significant in the treatment aimed towards enhancing the sexual drive in rats and
henceforth it is envisaged that it can be useful to humans suffering from the same
condition.
The extract were tested in vitro to establish the possible mode of action and the methanol-
dichloromethane extract was found to inhibit the phosphodiesterase 5 (POE 5) enzyme (68-
96%) and also effectively relaxed the pre-contracted smooth muscle (46-50%). It is
believed that one of the pathways essential to the treatment of erectile dysfunction is via
the inhibition of the POE 5 enzyme which then brings about the relaxation of the smooth
muscle. It was also noted that the commercial synthetic drug Viagra operates via the same
mode of action.
Phytochemical investigation of the extracts in order to identify the active components was
done specifically for the erectile dysfunction therapeutic area. The resulting five lignans
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showed varying degrees of the inhibition of the PDE 5 enzyme ranging between 11 and
53%. Four compounds, 5-methoxyjusticidin A (6.4, 62%), chinesinaphthol (6.6, 75%),
suchilactone (6.7, 71 %) and retrochinesinaphthol methyl ether (6.8, 57%) relaxed the
rabbit corpus cavernosum smooth muscle significantly. However, the effect on POE 5 and
rabbit corpus cavernosum smooth muscle was much lower than that of sildenatil (Viagra).
Furthermore, the water extract also show activity. As yet, we have not characterised the
water extract fully.
The compounds were also tested for their cytotoxic effect against a panel of three cell line
at the CSIR and only compounds, 5-methoxyjusticidin A (6.4) and justicidin A (6.5),
exhibited significant anticancer activity and specific for the melanoma cell line. 5-
Methoxyjusticidin A was selected by the National Cancer Institute, USA, for testing in
their 60 cell line screen, but research on this compound was not continued because of lack
of sufficient potency.
The lignans of the same structure framework as these isolated are amongst the compounds
researchers focus on. Podophyllotoxin and derivatives generally show cytotoxic effects but
are found in most fruits and foods as harmless derivatives in low concentrations. They
posses a wide range of biological activities such as anti-HIV, antimalaria, anti-
inflammatory and anticancer activity. Etoposide is a lignan glycoside structurally related to
the isolated compounds and is one of the clinically tested agents for the treatment of cancer
of the skin. 5-Methoxyjusticidin A (6.4), justicidin A (6.5), chinesinaphthol (6.6),
suchilactone (6.7) and retrochinesinaphthol methyl ether (6.8) also showed an interesting
pattern of cytotoxic activity and future work may focus on the synthetical modification of
their functional groups in order to provide derivatives with improved anticancer activity
but with lower toxicity.
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6.7. EXPERIMENTAL
HPLC-MS
The flow from the pump was split after the column with 90% going to the variable UV,
Waters 996 photodiode array detector (PDA) and 10% to the mass spectrometer. The
samples concentrations of 5000 ppm for the extracts and 2500 ppm for the fractions were
prepared by dissolving 5-10 mg of the sample in methanol-acetonitrile (I: I) and injecting
25 J.ll volumes on the column.
Plant material
Plant material was collected in the Free State by a traditional healer. The plant was visually
classified as a shrub with purple flowers and a specimen was deposited at SANBI in
Pretoria for identifications purposes. The plant was identified as Monsonia angustifolia
E.Mey. Ex A.Rich (Geraniaceae) (Genspec no. 39250002).
Extract preparations and isolation of compounds
The extracts were prepared from dried plant material (408 g) of Mansonia angusti/olia.
The plant parts supplied comprised of the roots, stems, leaves and purple flowers. The dry
plants were ground in a hammer mill to 1-2 mm pieces (352 g). The plant material was
extracted and partitioned as illustrated in Fig. 6.2.
The aqueous extract was prepared by a method similar to making a tea infusion. One liter
of de-ionized water was added to 86 g of the ground material and boiled for an hour. The
water solution was left to cool to room temperature, filtered and freeze-dried for 24 hours
to yield 22.16 g of a brownish fluffy powder (sample A).
The organic extract was prepared from 266 g of ground plant material that was extracted
with 6 L of methanol-dichloromethane (1: I v/v) for an hour with occasional stirring. The
solution was filtered and the residual plant material was extracted again with 3 L of
methanol-dichloromethane Cl: 1 v/v). The filtered solvents were combined and evaporated
under reduced pressure to give 27.32 g of a dark-green sticky extract (sample B).
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The organic extract (sample B, 1.5g) was partitioned between 1L of methanol-water (90%
v/v) and 500 ml of hexane. The hexane layer was separated and evaporated to yield 395.8
mg of a sticky greenish fraction (sample D). The methanol-water layer was evaporated
under reduced pressure. Water was added to this layer (total volume of 500 ml) and the
aqueous solution extracted with dichloromethane (3 x 500 ml). The combined
dichloromethane layers were evaporated under reduced pressure to yield 543 mg of a
brownish extract (sample C). The residual water was freeze-dried to give a brownish
powder (sample E, 474 mg).
The aqueous extract, sample A (200 mg) was dissolved in 2 ml of water and fractionated
on a C18 reverse phase silica gel flash cartridge using 100 ml of water, followed by 100
ml of methanol-water (1: 1 v/v) and 100 ml of methanol. A disaccharide was isolated from
the methanol fraction and it was identified as sucrose (6.10, 21 mg). The NMR data of
sucrose is collated in Table 6.7.
Fractionation of the orgamc extract (sample B, 6.0 g) was achieved on flash
chromatography (silica gel 60, Merck, 230-400mesh) with ethyl acetate-hexane mixtures
(1.5:8.5, v/v) as the eluent. P-Sitosterol (6.9,164 mg) and five lignans, 6.4 (35 mg), 6.5 (19
mg), 6.6 (27 mg), 6.7 (36 mg), 6.8 (16 mg) were isolated.
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35 mg (0.58%) relative to the extract
White amorphous solid
Amax 365, 263 and 237 nm.
m/z 424, C23H200 g
See Table 6.1 (CDC!))








See Table 6.2 (CDCI3)






Amax 322, 266 and 228 nm
(m/z) of 381, C2I H I60 7
See Table 6.3 (CDCh/CD30D)


































Amax 331, 257 nm
m/z 368, C21H2006
See Table 6.4 (CDCi))






Amax 316, 262 nm
m/z 395, C22H 1S0 7
See Table 6.5 (CDCi))
See Table 6.5 (CDCi))






See Table 6.9 (CDCl])








I H NMR data:
13C NMR data:
Other data:
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2-(3,4-Dihydroxy-2,5-bis-hydroxymethyl-tetrahydro-
furan-2-yloxy)-6-hydroxymethyl-tetrahydro-pyran-





See Table 6.7 (DMSO)
See Table 6.7 (DMSO)
See section 5.3.1.
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